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ABSTRACT 
CHARACTERIZATION OF NOVEL MONOCLONAL ANTIBODIES THAT 
TARGET PROTEINS DIFFERENTIALLY EXPRESSED IN HEPATOCELLULAR 
CARCINOMA: A PROTEOMICS APPROACH  
1.4ABSTRACT 
Emin Öztaş 
Ph.D. in Molecular Biology and Genetics 
Supervisor: Assist. Prof. Kamil Can Akçalı 
Co-Supervisor: Dr.Tamer Yağcı 
February 2011, 108 pages 
 
Hepatocellular carcinoma (HCC) is the sixth common cancer in the world. Because of the late 
diagnosis of the disease, survival rates are still poor in the HCC patients. Surveillance 
strategies have to be developed in populations with high risk groups having premalignant 
diseases for HCC, such as liver cirrhosis. The usage of serum and histology-based biomarkers 
assists health professionals to evaluate the patients. Despite of the advances in diagnostic 
methods, there is still a need to develop novel biomarkers for early detection of HCC. 
Therefore, we aimed to develop new biomarkers with higher sensitivity and specificity for 
HCC to improve the surveillance of the patients. Using an apoptotic HCC cell line, HUH7, 
and SIP1 proteins, we generated novel monoclonal antibodies (mAbs). 6D5, 1C6 and 6E5 
hybridoma clones were chosen for characterization studies because of their strong reactivity 
in cell-ELISA assays. We found differential reactivity pattern for those novel mAbs in a panel 
of human sections consisting of tumors, benign liver diseases, normal tissues and a variety of 
cell lines. Using proteomics methods, we identified candidate target proteins for the 6D5 
mAb. Better characterization of these target proteins will provide a better understanding of the 
molecular pathways in the HCC and aid in the research for developing newer therapeutic 
agents. In conclusion, our candidate biomarker mAbs can be used in the early diagnosis of 
HCC as well as in drug development studies. 
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ÖZET 
HEPATOSELÜLER KARSİNOMDA FARKLI EKSPRESE EDİLEN HEDEF 
PROTEİNLERİ TANIYAN MONOKLONAL ANTİKORLARIN KARAKTERİZE 
EDİLMESİ: PROTEOMİKS YAKLAŞIM 
1.5 ÖZET 
Emin Öztaş 
Moleküler Biyoloji ve Genetik Doktora Tezi 
Tez Yöneticisi: Yrd.Doç.Dr. Kamil Can Akçalı 
Yardımcı Yönetici: Dr.Tamer Yağcı 
Ocak 2011, 108 sayfa 
Hepatoselüler Karsinom (HK) dünyada en çok rastlanan tümörler arasında altıncı sırada yer 
alır. Bu hastalığın geç teşhis edilmesi nedeniyle HK’li hastaların yaşam süresi daha kısadır. 
Yaşam süresinin uzatılması yöntemlerinin geliştirilerek özellikle siroz gibi kansere neden olan 
hastalıkları taşıyan risk grubundaki insanlarda HK’nin erken teşhis edilmesi zorunludur. 
Serum ve histolojik çalışmalar dayalı biyobelirteçler geliştirilmesi sağlık çalışanlarına 
hastaların seçilmesinde yardımcı olur. Tanı metotlarındaki gelişmelere rağmen, HK’in erken 
tanısı için yine de yeni biyobelirteçlerin geliştirilmesine ihtiyaç vardır. Bu nedenle hastaların 
yaşam süresinin artırılmasına yardımcı olmak için HK’ne güçlü duyarlılıkta ve özellikte yeni 
biobelirteçleri geliştirmeyi amaçladık. Çalışmamızda apoptotik HK hücre hattı HUH7 ve SIP1 
proteinlerini kullanarak monoklonal antikorlar (mAk) ürettik. Hücre-ELISA testlerinde en 
güçlü reaksiyonu vermeleri nedeniyle 6D5, 1C6 ve 6E5 hibridoma klonlarını, karakterizasyon 
çalışmaları için seçtik. İnsan dokusu kaynaklı kanser, iyi huylu karaciğer hastalıkları, normal 
dokular ve hücre hatlarından oluşan panelde antikorlarımızın farklı şekilde reaksiyon 
gösterdiğini bulduk. Proteomiks metodlar kullanarak 6D5 mAk’nun bağlandığı hedef 
proteinler için adaylar tespit ettik. Sonuç olarak 6D5 ve SIP1 mAk’larımızın tumor belirteci 
olarak HK’nin erken tanısında kullanılabileceğini düşünmekteyiz. Ayrıca güncel tedavilere 
cevabın yetersiz olması nedeniyle, bizim yeni antikorlarımız HK’nin moleküler yolaklarının 
iyi anlaşılmasında ve yeni tedavi hedefleri geliştirilmesinde yardımcı olabilir. 
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1 INTRODUCTION 
1.1 Liver Anatomy and Histology 
The liver is the largest internal organ in the human body receiving blood supply from two 
major blood vessels. Oxygenated blood comes to the liver via hepatic artery, and the portal 
vein supplies deoxygenated nutrient-rich blood that provides the most part of the total blood 
supply of the liver. The Glisson’s capsule, a connective tissue, surrounds the liver. This 
capsule separates the liver into polygonal lobules by connective tissue expansions. The 
periphery of the polygonal lobule consists of the portal vein, the hepatic artery, bile ducts, 
lymphatics and nerves. The central vein is located at the center of the lobule. The lobule 
consists of the parenchymal hepatocytes and nonparenchymal supporting cells. Hepatocytes 
are the most important cells in the liver and occupy almost 80% of the total volume of the 
liver and play role in numerous liver functions. On the other hand 6.5% of the liver volume 
consists of nonparenchymal cells which form 40% of the total liver cells. These cells are 
localized in the sinusoidal compartment of the tissue. Hepatic sinusoids are covered by three 
seperate cell types. These are sinusoidal endothelial cells (SEC), Kupffer cells (KC), and 
hepatic stellate cells (HSC) (Fig.1.1) (Bowen, McCaughan et al. 2005). In addition, sinusoidal 
lumen homes liver-specific natural killer cells. Neighboring nonparenchymal cells release 
substances that regulate the functions of the hepatocytes in normal and disease conditions. 
Liver sinusoidal endothelial cells constitute the lining or wall of the hepatic sinusoid (Lautt 
1977). 
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Figure 1.1 Cellular structure of the liver (Bowen, McCaughan et al. 2005). 
 
1.1.1 Functions of Liver 
Liver plays a central role in many vital physiological processes as a guard between the 
digestive system and rest of the body (Vekemans and Braet 2005). The liver functions in 
energy production and detoxification. It synthesizes lipoproteins, many plasma proteins, 
especially albumin, clotting factors, as well as cholesterol, glycogen, urea and certain amino 
acids. Liver changes, transforms and detoxifies many endogenous and exogenous substances. 
It synthesizes and secretes bile acids (Sasse, Spornitz et al. 1992). In addition it stores lipid 
soluble vitamins and many minerals. Some other functions of the liver are regulating fat 
metabolism, protein metabolism, carbohydrate metabolism, besides activation of enzymes 
important for many metabolic processes (Trauner, Fickert et al. 2001). 
1.1.2 Disease Conditions of Liver 
Liver has various pathological conditions including, inflammatory (hepatitis), cirrhotic 
(chronic inflammation progressing into organ failure), carcinomatous (originating from liver 
or metastatic), or storage (of fats, glycogen, metals) diseases. Chronic alcoholism is a 
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metabolic perturbant for the liver functions. Hepatocellular carcinoma (HCC) is a primary 
hepatic neoplasm and the most known type of liver cancer besides intrahepatic bile duct 
carcinoma, bile duct cystadenomacarcinoma hepatoblastoma, hemangiosarcoma and 
epitheloid hemangioendothelioma (Anthony 2002; Jemal, Siegel et al. 2010). 
1.1.3 Hepatocellular Carcinoma 
HCC is described as the malignant tumor of liver originating from liver parenchyma, 
hepatocytes. It is a primary malignant epithelial neoplasm of the liver. The macroscopic 
appearance of HCC varies according to the size of tumor and the presence or absence of liver 
cirrhosis. HCC may arise as a single mass, multinodular, with many tumors scattered through 
the liver, or as a diffusely growing lesion (Wilkens, Bredt et al. 2000). Histological view of 
HCC is variable, with various architectural and cytological patterns. Trabecular pattern is the 
most known architectural variant. Tumor cells of HCCs may demonstrate fatty or clear cell 
changes. Its histology also shows various forms, like chronic hepatitis and or cirrhosis of 
dysplastic regions besides adenomatous hyperplasia (Feitelson, Sun et al. 2002; Levy, Renard 
et al. 2002). Different cytological variants within the same tumor are frequently exhibited in 
HCCs. The most important differential diagnosis in well-differentiated HCCs is the liver cell 
adenoma and dysplastic nodules. Moderately differentiated HCCs rarely bring diagnostic 
problem, whereas poorly differentiated HCCs have to be differentiated from other solid, 
growing, poorly differentiated carcinomas (Rocken and Carl-McGrath 2001). 
1.1.3.1 Pathogenesis of Hepatocellular Carcinoma 
The pathogenesis of HCC, being multifactorial, involves environmental, infectious, 
metabolic, endocrine and nutritional factors that contribute to carcinogenesis. The importance 
of each factor varies geographically depending on the environmental and socioeconomic 
influence. High incidence of HCC is detected in African and Far Eastern countries where 
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hepatitis B virus (HBV) and/or hepatitis C virus (HCV) infections are endemic. In these areas, 
alflatoxin B1, alcoholism, and inherited metabolic diseases, such as hemochromatosis, 
tyrosinemia, and lipid storage diseases are common etiology for the development of HCC 
(Wong, Lai et al. 1999; Thorgeirsson and Grisham 2002). Recent studies have brought some 
understanding for the involvement of HBV in liver malignancies. New oncogenic pathways 
and tumor suppressor networks were reavealed besides chromosomal abnormalities in HCC 
(Zimonjic, Keck et al. 1999; Levy, Renard et al. 2002). 
1.1.3.2 Genomic Changes in Hepatocellular Carcinoma 
Cancer develops in the living organism as a result of clonal proliferation of cells acquiring 
selection for growth as a result of genetic alterations such as mutations in oncogenes and 
tumor suppressor genes (Buetow, Murray et al. 1989). Identification of genes altered during 
tumor progression is essential to illuminate the molecular events in carcinogenesis (Yokota 
2000). Genetic alterations such as amplification, deletion, translocation and rearrangement in 
certain chromosomal regions can result in gain or loss of function in genes that modulate cell 
proliferation, differentiation, motility and survival (Crawley and Furge 2002). Tumor 
suppressor genes are inactivated somatically, usually via mutations in one allele of the gene 
and by loss of a region belonging to the second allele. HCCs show variable alterations in the 
genome, involving rearrangements in DNA, loss of heterozygosity (LOH), amplification in 
chromosomes, lack of imprinting and many other mutations. Various genes have been 
proposed in the pathological steps of HCC (Kawamura, Nagai et al. 1999). Chromosomal 
abnormalities and genetic instability in HCC, such as aneuploidy is a well-known feature of 
cancers including HCC. Chromosome abnormalities in HCCs are summarized in Table1.1. 
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Table 1.1 Review of chromosomal abnormalities in HCCs (http://etd.lib.nsysu.edu.tw/ETD-
db/ETD-search/view_etd?URN=etd-0728103-150443). 
Sample 
type Methods 
Position 
Gain Loss 
HCC cell 
lines 
CGH 
RxFISH 
1, 6p, 7q, 8q, l0p, 17q, 20 4q21, 13, 18q21,Y 
HCC cell 
lines 
CGH,  
FISH 
lp34.3-35, lp33-34.1, lq21-23, 
1q31 -32, 6p11-12, 7p21, 7ql 
1.2, 8q24.1-24.2, llqll-13, 12ql 
1-13, 12q23, 17ql 1.2-21, 
17q23-24, 20pll.l-ql3.2 
3pl2-14, 3q25, 4pl2-14, 4ql3-
34, 5q21, 6q25-26, 8pl 1.2-23, 
9pl2-24, llq23-24, 13ql2-33, 
14ql2-13, 15q25-26, 18qll.2-
22.2, 21q21-22 
HCC CGMA lq, 6p, 8q, 17q, 5q, 12q, 19p 4q, 8p, 13q, 16q, 17p 
HCC CGH lq24-25, 8q24, llql3 17p, 16q, 13ql3-14, 4ql3-22, 8p, l0q 
HCC CGH lq, 3q25, 4pl5, 6p21-23, 7, 8q, 
10q24, llpl4, 12q, 13q31-32, 
16p, 17q, 18p 11, 19pl0, 20q, 
Xp21 
lp, 4q, 5ql3-23, 6ql3-23, 8p21-23, 
9p, 10q22-23, 11ql 4-22, 12ql4-21, 
13q, 14q21-23, 18q12-21, 21qll, 
Y 
HCC CGH lq, 8q, 17q, 20q 4q, 8p, 13q, 16q 
HCC MSA 1p, 1q, 2q, 3p, 4q, 6q, 8p, 9p, 13q, 16q, 17p with LOH 
HCC MSA 1p, 4q, 6q, 8p23, 13q, 16p with LOH 
HCC MSA lq, 5q, 6p, 7, 8q lp, 8p, 17p 
HCC CGH, 
FISH 
1ql2-q22, 8q, 20q 16q, 17p, 19p, 4q, lp, 8p 
HCC MSA 1p33, 1q22-24, 1q25-41, 4q13-23, 4q28, 4q32-qter, 6p24-25, 8p21-
23, 8p11-cen, 8q22-24.1, 9p22, 9q31, 10q23.3, 13q14-qter, 16q, 
17p with LOH 
HCC CGH, 
MSA 
lq, 17p, 8q24 17p, 9p21-23, 4q, 16q21-23.3, 
13q, 8p21-23, 6q24-27 
HCC MSA, 
CGH 
6q, 8q, 10p, 13q, 17q 4q, 5q, 7q, 9q, 1 lq, 16q 
HCC MSA 1p, 4q, 8p, 17p, 13q, 14q, 9p, 16p, 3p, 8q, 5q, 10q, 11p, 18, 7q 
with LOH in biologic indicators of HCC 
HCC: hepatocellular carcinoma, CGMA: comparative genomic microarray analysis, CGH: 
comparative genomic hybridization, FISH: fluorescence in situ hybridization, LOH: Loss of 
hetrozygosity, RxFISH: cross-species color banding, MSA: microsatellite analysis 
 
 
6 
 
1.1.4 Serum Markers for Hepatocellular Carcinoma 
The prognosis of advanced HCC is poor, however, smaller HCC appropriate for organ 
transplantation, surgical resection or radio frequency ablation has a better prognosis and 
longer survival. For this reason detection of HCC at an early stage seriously affects the 
clinical outcome of these patients (Mor, Kaspa et al. 1998). Therefore, a surveillance program 
using alpha fetoprotein (AFP) and ultrasound in every six months has been recommended by 
a consensus conference, and is widely practiced (Bruix, Sherman et al. 2001). Using a 
biomarker is particularly beneficial for the diagnosis of HCC in high risk patients with liver 
cirrhosis, a premalignant condition (Fattovich, Stroffolini et al. 2004). Surveillance programs 
seem to be cost-effective but whether they increase survival is still debated. Recently, it has 
been suggested that surveillance costs are mostly due to HCC treatment rather than the 
surveillance tests (Patel, Terrault et al. 2005). However, this conclusion depends also on the 
fact that the diagnostic tests available so far are not beneficial for early detection of HCC, thus 
affecting the treatment choice, the clinical outcome and the cost-effectiveness. In the case, 
clinicians have to balance the ethics of an earlier diagnosis while also considering the cost–
benefit issues. So far AFP, the only serological marker commonly used in diagnosis may not 
be a reliable marker mostly because of its poor sensitivity, ranging from 39% to 65% and a 
specificity ranging from 76% to 97% (Daniele, Bencivenga et al. 2004; Marrero and Lok 
2004). AFP seems to be reliable at values over 400 IU/ml; however the percentage of patients 
with such high levels is very small; this is one of the most important limits of this marker. It is 
no doubt that ultrasonography is a very powerful technique to identify nodules raising a 
suspicion of HCC, and technical improvements of diagnostic devices, e.g. use of contrast-
enhanced ultrasonography, will further improve the diagnostic accuracy. However, ultrasound 
has also its major limits, as good results depend on technological advances of the device and 
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the skill of the operator. Therefore, combination of ultrasound with serological markers such 
as AFP seems to be the best choice. Serum markers of HCC are summarized in Table 1.2. 
 
Table 1.2 Hepatocellular carcinoma markers (Malaguarnera, Giordano et al. 2010) 
HCC marker Principal use 
Alpha-fetoprotein HCC early diagnosis, monitoring, and 
recurrence 
Lens culinaris agglutinin reactive AFP 
(AFP-L3%) 
HCC early diagnosis and prognosis (vascular 
invasion and intrahepatic metastasis) 
Des-γ-carboxy prothrombin (DCP) HCC early diagnosis and prognosis (early 
portal vein invasion and metastasis) 
α-l-fucosidase HCC early diagnosis 
Glypican-3 HCC early diagnosis 
P-aPKC-ı, E-chaderin, β-catenin HCC prognosis 
Human carbonyl reductase (HCR2) HCC prognosis 
Squamous cell carcinoma antigen (SCCA) HCC early diagnosis 
Serum proteomics HCC early diagnosis 
Golgi protein 73 HCC early diagnosis 
Chromogranin A (CgA) HCC prognosis and possible therapeutic 
treatment 
Vascular endothelial growth factor (VEGF) HCC prognosis (metastasis development) 
Hepatocyte growth factor (HGF) HCC prognosis and disease recurrence 
Transforming growth factor-β (TGF-β) HCC progression 
Serum anti-p53 HCC prognosis (poor differentiation) 
Nerve growth factor (NGF) HCC prognosis and progression 
β2-microglobulin (β2MG) HCC progression 
Glycylproline dipeptidyl aminopeptidase 
(GPDA) 
HCC early diagnosis 
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1.2 SIP1 as a Tumor Marker  
SMAD interacting protein 1 (SIP1), also known as ZEB2, encoded by ZFHX1B, is a member 
of ZEB family of transcription factors. The protein contains a central homeodomain, CtBP-
binding and Smad-interacting domains and two zinc finger clusters each at either end 
(Remacle, Kraft et al. 1999; Verschueren, Remacle et al. 1999). SIP1 directly binds to 
bipartite E-boxes on the promoters of different targets by means of its zinc finger domains and 
mediates transcriptional repression (Verschueren, Remacle et al. 1999). One of these targets is 
CDH1, the gene encoding for the epithelial adherens junction protein, E-cadherin, whose 
transcriptional downregulation induces epithelial-to-mesenchymal transition (EMT) in 
developmental processes and during tumor cell invasion and metastasis (Comijn, Berx et al. 
2001). Transcriptional repression is mediated through the association of SIP1 with the 
corepressor CtBP, however this interaction is dispensable at least for the attenuation of CDH1 
transcription (Postigo, Depp et al. 2003; van Grunsven, Michiels et al. 2003). Overexpression 
of SIP1 in epithelial cells has also been shown to downregulate constituents of cell-cell 
junctions other than E-cadherin (Vandewalle, Comijn et al. 2005). Although binding of SIP1 
to p300 or pCAF was proposed as a mechanism for transactivation and other transcriptional 
activators associated to SIP1 are yet to be determined, SIP1-mediated up-regulation of EMT 
and invasion related genes, such as vimentin and matrix metalloproteases, have been reported 
(Postigo, Depp et al. 2003; Miyoshi, Kitajima et al. 2004; Bindels, Mestdagt et al. 2006).  
Despite the overwhelming evidence that SIP1 induces EMT phenotype, its role in 
tumorigenesis was ill-defined. In fact, SIP1 was originally identified as a binding partner of 
R-Smads, and shown to be part of the TGF-β pathway, which is frequently involved in 
carcinogenesis (Verschueren, Remacle et al. 1999). hTERT repression in breast cancer cells 
was partly mediated by SIP1 in a TGF-β dependent manner (Lin and Elledge 2003). Also, 
analysis of senescence arrest of clonal HCC cells revealed SIP1 as a mediator of hTERT 
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repression (Ozturk, Erdal et al. 2006). Impaired G1/S progression was observed upon 
repression of cyclin D1 by SIP1 (Mejlvang, Kriajevska et al. 2007). SIP1 was also shown to 
contribute to tumorigenesis in a transgenic mouse model of lymphoma by retroviral tagging 
(Mikkers, Allen et al. 2002). The differential expression of SIP1 has been described, mostly 
by RT-PCR, in several human tumors due to the lack of human SIP1-specific antibodies. E-
cadherin down-regulation was associated with increase SIP1 expression in intestinal type 
gastric carcinoma but not in diffuse type gastric carcinoma (Rosivatz, Becker et al. 2002). 
Elevated SIP1 expression correlated inversely with E-cadherin in advanced stages of 
pancreatic tumors (Imamichi, Konig et al. 2007). Surprisingly, SIP1 and E-cadherin 
expression were positively correlated in malignant mesothelioma (Sivertsen, Hadar et al. 
2006). In the esophagus, differential expression of SIP1 was observed during keratinocyte 
differentiation. Only stem cell containing basal cells, but not parabasal cells and keratinocytes 
expressed SIP1. Consistent with this, SIP1 transcripts were present in all studied esophageal 
carcinoma cases (Isohata, Aoyagi et al. 2009). High SIP1/E-cadherin ratio correlated with 
metastatic disease and poor patient survival in breast and ovarian carcinomas (Elloul, Elstrand 
et al. 2005). Elevated SIP1 transcripts were observed in von Hippel-Lindau-null renal cell 
carcinomas in a hypoxia-inducible factor 1 alpha (HIF1α)-dependent manner 
(Krishnamachary, Zagzag et al. 2006). Immunohistochemical analysis of ovarian tumors 
revealed a stepwise increase of SIP1 from benign to borderline and to malignant tumors 
(Yoshida, Horiuchi et al. 2009). In oral squamous cell carcinoma, SIP1 was 
immunohistochemically detected in a relatively low proportion of tumors and its expression 
correlated with poor prognosis (Maeda, Chiba et al. 2005). In a previous study, it is found that 
SIP1 was overexpressed in a series of bladder cancers. Its expression was found to be an 
independent prognostic factor in bladder cancers and positively stained cases correlated with 
poor therapeutical outcome (Sayan, Griffiths et al. 2009). With the exception of a few and as 
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described above, most of the expression studies of SIP1 were done using RT-PCR technique, 
but SIP1 protein levels have been shown to be tightly regulated by post-transcriptional 
mechanisms. For instance, Pc2-mediated sumoylation of SIP1 affects the transcriptional 
regulation of E-cadherin (Long, Zuo et al. 2005). In addition SIP1 also has been identified as 
a direct target of miR-200 family and miR-205 (Gregory, Bert et al. 2008; Park, Gaur et al. 
2008).  
1.3 Biomarker Research 
A tumor marker is a substance produced by tumor or by host tissue as a response, detectable 
in biological fluids or tissues and useful to differentiate neoplastic from non-neoplastic 
disease. These markers are commonly used in diagnosis, staging and prognosis of cancer, and 
can be useful to localize the tumor burden, besides monitoring therapeutic effectiveness, 
detecting recurrence or localizing of the tumor, and screening the general population or 
groups at risk. Tumor markers, also named biomarkers, have been classified as enzymes, 
isoenzymes, hormones, oncofetal antigens, carbo-hydrate epitopes, oncogene products and 
genetic alterations. Unfortunately, until now, none of the known biomarkers fit the ideal 
specificity profile. The most important characteristics for a biomarker are measurement by 
simple techniques, reliability, reproducibility, minimal invasiveness and low cost. Novel 
biomarkers are continuously suggested by powerful, high-technology research. 
1.3.1 Monoclonal Antibodies 
In 1975 the hybridoma technique was introduced (Kohler and Milstein 1975). This strategy 
utilizes a hybrid cell line to produce an antibody clone with desired binding properties. 
Hybridomas are obtained by fusion of a selected antibody-producing B cell with an immortal 
myeloma cell (a cancerous plasma cell). Thereby, an infinite source of antibody molecules is 
obtained. In many applications, including diagnostics or therapeutic applications, monoclonal 
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antibodies (mAbs) are preferred (Borrebaeck 2000). This is because of the renewable source 
and the fact that monoclonal antibodies recognize one single epitope on the target. The 
detection of the epitope is assumed to give information about the target protein. On the other 
hand, in applications where multi-epitope recognition is desired more than one monoclonal 
antibody or a polyclonal serum is required. Monoclonal antibodies are used in many aspects 
of biomedical research, in diagnosis, and in treatment of diseases, such as infections and 
cancer. Antibodies are important tools for research and have led to many medical advances.  
1.3.2 Analysis of Monoclonal Antibody Targets  
1.3.2.1 Tissue Microarrays 
Method of using tissue microarrays (TMAs) presents as a technology which allows for the 
linking of clinical data to the tissues that are combined on one slide. Tissue microarrays have 
become a tool for tissue-based research since the last decade. In cancer research, depending 
on the available data attached to the arrayed tissue, many types of arrays from different tissues 
are commonly manufactured. Prevalence TMAs are suited to estimate the frequency of the 
occurrence of a particular alteration. Progression arrays include tissues of different stages of 
disease, and are useful to study the role of a marker protein for tumor initiation, progression, 
or metastatic growth. Prognosis TMAs include tissues with patient follow-up data. These 
TMAs are the key components to uncover the clinical impact of molecular markers. In 
combination with normal tissue arrays representing healthy tissues, prevalence, progression, 
and prognosis TMAs all allow to a rapid and comprehensive analysis of molecular markers in 
human cancers. TMAs are also successfully used in many noncancer applications, such as 
Alzheimer’s or inflammatory disease research. 
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1.3.2.2 Epitope Mapping with Protein Microarrays 
Epitope Mapping is a method used for studying the interactions of antibodies with specific 
regions of protein antigens. Important applications of epitope mapping are found within the 
area of immunochemistry. 
Protein (peptide) microarrays are powerful tools for characterizing antibodies raised against 
protein antigens. For antibody targets epitope mapping, an array is made from a library of 
short peptides that span the antigenic protein sequence (Martens, Greiser-Wilke et al. 1995; 
Frank and Overwin 1996; Reineke, Ivascu et al. 2002). The antigenic determinant recognized 
by a mAb can then be defined by probing the array with the antibody. An epitope can be 
defined by constructing an array in which each epitope residue is substituted with other amino 
acids to assess that residue’s contribution to antibody binding and to determine which 
substitutions affect antibody recognition (mutational analysis). Antibody cross-reactivity can 
be evaluated with arrays made from large numbers of unrelated synthetic peptides.  
Protein microarrays constitute a technology with in situ protein expression directly on the 
surface of polyvinylidene fluoride (PVDF) membranes. Protein synthesis is performed in an 
E. coli based expression system for recombinant proteins. In this system, a tagged human 
fusion proteins were expressed in E. coli, and after native lysis with lysozyme, crude protein 
extracts were prepared under non-denaturing conditions in 384-well plate format. The crude 
bacterial cell extracts were used for incubation overnight with the high density spotted PVDF 
membranes. The protein microarrays can be used for epitope mapping. The redundant nature 
of the cDNA expression library represented on protein microarrays allows identification of 
the epitopic region and determination of possibly shared epitopes in cross-reacting proteins 
(Bussow, Cahill et al. 1998). Furthermore the protein sequences of the corresponding clones 
can be used to design different peptides to find the specific epitope recognized by the 
antibody (Grelle, Kostka et al. 2006). 
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1.3.2.3 Proteomics Analysis 
The “proteome” term is generally attributed to Mark Wilkins, who introduced the term 
“proteoma” at the Siena Conference in 1994 (Wasinger, Cordwell et al. 1995). Through 
borrowing the semantics from the ‘genome’ term, it becomes clear that the scope of research 
is very similar in both cases, although the topics differ. Indeed, it is imperative to analyze the 
protein content of a cell in order to understand its structure at the molecular level. Analyzing 
the proteome introduces a more daunting challenge compared to analyzing the genome: apart 
from spanning a large concentration range, at least 10 orders of magnitude in plasma (States, 
Omenn et al. 2006), it is dynamic in concentration besides modification state. Indeed, even 
though cells have the same genome, their proteomes can be different markedly (Collins 2001). 
Besides, protein sequences are not easily duplicated to large copy-numbers as is the case for 
nucleic acid sequences through the application of the polymerase chain reaction (PCR). 
Nowadays the most popular technique to study the proteome is mass spectrometry that relies 
on separating charged ions by their mass-to-charge ratio (m/z). The general structure of gel 
based proteome analysis is schematized in Fig.1.2. 
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Figure 1.2 Gel based proteome analysis 
 
1.3.2.3.1 Two-dimensional Polyacrylamide Gel Electrophoresis  
Two-dimensional polyacrylamide gel electrophoresis (2D-PAGE) has been in charge of 
proteomics research for over three decades (O'Farrell 1975; Klose and Kobalz 1995). Its 
ability in separating complex protein mixtures in two dimensions according to various 
physicochemical properties was supported by protein identification via mass spectrometry. 
The separation using 2D-PAGE is based on protein iso-electric point (pI) in the first 
dimension (isoelectric focusing, IEF) and on apparent molecular weight (SDS-PAGE) in the 
second dimension. In a typical analysis, a protein mixture is first run on a 2D-PAGE system 
and after separation the resulting proteome pattern is visualized by staining, e.g. by 
Coomassie brilliant blue and silver staining (Meyer and Lamberts 1965; Switzer, Merril et al. 
1979). After the visualized protein spots are excised, proteolytic digestion follows either by 
dissolving the proteins from the gel or, directly inside the gel (in-gel digestion). The 
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proteolytic enzyme preferred is usually trypsin, which cleaves on the carboxy-terminal (C-
terminal) side of arginine or lysine (Olsen, Ong et al. 2004) generating peptides with one of 
these basic amino acids. This is useful while making the step to mass spectrometry which can 
only analyze charged ions. Then identification of isolated protein(s) proceeds through a 
matching of the peptide masses measured by the mass spectrometers to the masses of the in 
silico produced cleavage products obtained from the entries in a protein sequence database. 
This comparison is usually too hard to perform manually and specialized software has been 
generated to allow the automated matching of peptide masses to protein databases (Mann, 
Hojrup et al. 1993; Pappin, Hojrup et al. 1993; Yates, Speicher et al. 1993; Clauser, Baker et 
al. 1999; Colinge, Masselot et al. 2003; Geer, Markey et al. 2004). Such algorithms usually 
need a coverage factor into account when scoring a protein hit. This stems from the 
assumption that proteins are isolated in pure form after the 2D separation. 2D gel-based 
methods have proved their usefulness over time  
1.3.2.3.2 Mass Spectrometry 
Mass spectrometer can be classified into three parts: ion source, m/z analyzer and detector. 
The detector is usually a specific type of electron multiplier. Due to the high amplification 
that is typically required, most modern instruments use a type of microchannel plate detector. 
Additional refinements for peptide/protein sequence analysis include so-called tandem- MS or 
MS/MS instruments which are capable of more than one round of mass spectrometry. In this 
technique one mass spectrometer isolates a peptide of a particular m/z, while a second mass 
spectrometer is used to catalog fragment ions resulting after induced or spontaneous 
fragmentation. When applied to biomolecular compounds, the ion source of the mass 
spectrometer can typically take two forms: a Matrix-Assisted Laser Desorption and Ionisation 
(MALDI) source (Karas and Hillenkamp 1988) or an ElectroSpray Ionisation (ESI) source 
(Fenn, Mann et al. 1989). In a MALDI source, energy from laser light is converted into 
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kinetic energy of the irradiated molecules/ions. This light is directed towards a metallic target 
plate on which the analyte has been crystallized in the presence of so-called matrix molecules. 
The laser light itself is typically derived from a N2 laser generating UV light with a 
wavelength of 337 nm. Some often-used matrix compounds are -cyano-4-hydroxycinnamic 
acid for peptide analytes (Beavis and Chait 1990) and sinapinic acid (3,5-dimethoxy-4-
hydroxycinnamic acid) for proteins (Beavis and Chait 1989). Crystallization is usually 
performed in highly organic solvents and in the presence of 0.1% tri-fluoroacetate (TFA). The 
actual mechanisms leading to desorption and ionisation are subject of debate (Karas 1996; 
Zhao, Kent et al. 1997; Salih, Masselon et al. 1998; Wong, Lee et al. 1999), yet it is thought 
to rely on efficient absorption of the laser energy by the matrix molecules, which ultimately 
convert it into kinetic energy. This theory explains why a high molar excess of matrix 
molecules is required to obtain efficient desorption of the analyte. Ionisation might, according 
to one hypothesis, occur in the gas phase by proton transfer between the acidic matrix ions 
and the basic residues of the analyte (lysine, arginine or histidine). The principle of a MALDI 
source is depicted according to this theory in Fig 1.3.  
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Figure 1.3 MALDI principles for protein analysis 
 
1.3.2.3.3 Identification of Proteins 
The process of converting mass spectrometry data into protein lists is managed by two 
important items: software algorithms that consider establishing mass spectra and, the protein 
sequence databases that they take as search space. The different types of identification 
algorithms besides the importance and characteristics of protein sequence databases are 
available to analyze the mass spectrometry results.  
1.3.2.3.4 Protein Sequence Databases 
Protein identification is usually based on database search algorithms. Interestingly, even 
though the sequence database employed represents the most basic source of information in 
these identifications, its importance is often disregarded. The European Bioinformatics 
Institute (EBI) has developed and maintained a number of protein related databases (Table 
1.3). 
Table 1.3 The list of protein related databases (http://www.ebi.ac.uk/Databases/protein.html). 
Database Description
CluSTr Offers an automatic classification of UniProtKB/Swiss-Prot + 
UniProtKB/TrEMBL. 
CSA CSA - The Catalytic Site Atlas is a resource of catalytic sites and 
residues identified in enzymes using structural data.  
HPI Human Proteomics Initiative (HPI) is an initiative, by SIB and the 
EBI, to annotate all known human sequences according to the quality 
standards of UniProtKB/Swiss-Prot. 
IntEnz The Integrated relational Enzyme database (IntEnz) will contain 
enzyme data approved by the Nomenclature Committee. The goal is 
to create a single relational enzyme database. 
InterPro The InterPro database is an integrated documentation resource for 
protein families, domains and functional sites. 
IPI International Protein Index contains a number of non-redundant 
proteome sets of higher eukaryotic organisms constructed from 
UniProtKB/Swiss-Prot, UniProtKB/TrEMBL, Ensembl and RefSeq. 
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LGICdb The Ligand Gated Ion Channel Database. 
PANDIT PANDIT - Protein and Associated Nucleotide Domains with Inferred 
Trees. PANDIT is a collection of multiple sequence alignments and 
phylogenetic trees covering common protein domains. 
Patentdata Resources Patent data resources at EBI contain patent abstracts, patent chemical 
compounds, patent sequences and patent equivalents.  
UniProt The Universal Protein Resource for protein sequences and is the 
central hub for the collection of functional information on proteins, 
with accurate, consistent, and rich annotation, the amino acid 
sequence, protein name or description 
UniProt Archive A non-redundant archive of protein sequences extracted from public 
databases and contains only protein sequences. 
UniProt/UniRef Features clustering of similar sequences to yield a representative 
subset of sequences. This produces very fast search times. 
UniProtKB-GOA Provides assignments of proteins in UniProtKB/Swiss-Prot, 
UniProtKB/TrEMBL and IPI to the Gene Ontology resource. 
UniProtKB/Swiss-Prot An annotated protein sequence database. Part of the UniProtKB. 
UniProtKB/TrEMBL A computer generated protein database enriched with automated 
classification and annotation. Part of the UniProtKB. 
UniProt/UniMES A repository specifically developed for metagenomic and 
environmental data. 
UniSave The UniProtKB Sequence/Annotation Version Archive (UniSave) is a 
repository of UniProtKB/Swiss-Prot and UniProtKB/TrEMBL entry 
versions. 
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2 OBJECTIVES AND RATIONALE 
 
Hepatocellular carcinoma is one of the most common cancers with high morbidity and 
mortality rates and, its incidence is increasing worldwide (O'Brien, Kirk et al. 2004). It is the 
fifth most frequent cancer in the world and the third most common cause of cancer-related 
deaths (Parkin 2001). Liver cirrhosis is the most important risk factor for HCC development 
and will possibly remain so in next decades, due to the high frequency of hepatitis B and C 
viral infections and excessive alcohol intake (Donato, Tagger et al. 2002; Davila, Morgan et 
al. 2004). The major contributing phenomenon to this expectancy is the long latency period 
between infections and the onset of HCC (El-Serag and Mason 2000). For these reasons, 
patients with liver cirrhosis are periodically surveilled for the diagnosis of HCC at early 
stages of tumor development. For instance, serum α-fetoprotein levels (AFP) and hepatic 
ultrasonography are the screening tools of choice (Okazaki, Yoshino et al. 1990) yet, other 
promising biomarkers, such as des-gamma carboxyprothrombin (Lefrere, Conard et al. 1988), 
lens culinaris-agglutinin reactive AFP (Kuromatsu, Tanaka et al. 1993), human hepatocyte 
growth factor-1 (HGF-1) (Wennerberg, Nalesnik et al. 1993) insulin-like growth factor-1 
(IGF-1) (Wee and Nilsson 1997) and glypican-3 (Borscheri, Roessner et al. 2001) are 
currently under intensive investigation. Although useful, these tumor markers have poor 
sensitivity and specificity for HCC, and accordingly, their use for differential diagnosis of 
malignant liver cancers are limited (Okazaki, Yoshino et al. 1990; Borscheri, Roessner et al. 
2001). Therefore, the development of novel markers for HCC with higher sensitivity and 
specificity is of great importance for the surveillance of patients with chronic hepatitis and 
liver cirrhosis, which are at high risk to develop liver tumor. The use of serological markers in 
patients at the highest risk for developing HCC can thus decrease the cancer-related mortality 
and reduce medical costs. 
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We recently generated 3 new monoclonal antibodies (mAb) by using cells of HUH7, a HCC 
cell line, and recombinant SIP1 proteins as immunogen against novel targets in HCC. To 
validate their specificity we explored the expression pattern of novel mAbs in human tumor 
cell lines and in a variety of tissues. In addition to expression profile of these mAbs in tissue 
sections and cell lines, we aimed to explore the targets (epitopes) of the 6D5 mAb by using 
proteomics methods. For this reason, the most commonly used proteomic technologies, 
including protein microarrays, two-dimentional gel electrophoresis and mass spectrometry 
were applied into this study for the discovery of new diagnostic markers of HCC and targets 
of pharmaceutical interest to improve patients’ prognosis.  
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3 MATERIALS AND METHODS 
 
3.1 MATERIALS 
Immobiline pH-gradient (IPG) DryStrips (pH3-10, length 7 cm), IPG buffer (pH3-10), 
DryStrip cover fluids, thiourea, urea, CHAPS, DTT, Pharmalyte (pH 3-10), bromophenol 
blue, Bis, TEMED, Coomassie brilliant blue G-250, protein molecular weight marker, Tris-
base, SDS, glycine, horseradish peroxidase-conjugated goat anti-rabbit IgG, horseradish 
peroxidase-conjugated goat anti-mouse IgG, and the enhanced chemiluminescence (ECL) 
system were purchased from Amersham Biosciences (Stockholm, Sweden). For 
immunohistochemistry, secondary antibodies with biotin-avidin complexes and chromogen 
diaminobenzidine (DAB) were used in universal staining kit purchased from (LabVision, 
Fremont, CA). Sequencing-grade modified trypsin was obtained from Promega (Madison, 
WI). PVDF membrane and ZipTip C18 columns were obtained from Millipore (Boston, MA). 
Mercaptoethanol (ME), iodoacetamide (IAA), Acetic Acid, Ammonium Bicarbonate, R-
cyano-4-hydroxycinnamic acid (CCA), and HCl were from Sigma-Aldrich (St. Louis, MO). 
HPLC Acetonitrile (ACN), HPLC Water (Burdick&Jackson), DTT (Calbiochem), TFA 
(Pierce). All buffers were prepared with Milli-Q water.  
3.1.1 Electrophoresis, Autoradiography, Photography and 
Spectrophotometer 
Electrophoresis grade agarose was obtained from Sigma Biosciences Chemical Company Ltd. 
(St. Louis, MO). Horizontal electrophoresis apparatus were from E-C Apparatus Corporation 
(Florida, USA). An imaging system, Vilber Lourmat (France), was used to image and 
analyze. The power supply Power-PAC300 and Power-PAC200, Mini-PROTEAN3 cell 
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system, programmable IEF unit Protean II IEF cell and Trans-Blot SD semi-dry 
electrophoretic transfer cell were purchased from Bio-Rad (CA, USA). Univapo 100 ECH 
vacuum concentrator centrifuge was from UniEquip GmbH (Germany). Immobilon-P transfer 
(PVDF) membrane was from Millipore (MA, USA) and 3M filter paper was from Whatman 
International Ltd. (Madison, USA). The films used for autoradiography were from Kodak and 
the development of the films was performed with Hyperprocessor (Amersham, UK). ECL-
Plus, Western Blotting detection reagent was purchased from GE Healthcare Life Sciences 
(Buckinghamshire, UK). Beckman Spectrophotometer Du640 was from Beckman Instruments 
Inc. (CA. USA) and Nanodrop ND-1000 Full-spectrum UV/Vis Spectrophotometer was from 
Thermo Fisher Scientific (Wilmington, DE).  
3.1.2 Tissue Culture Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), RPMI 1640, trypsin, non-essential amino 
acids, penicillin/streptomycin mixture and fetal calf serum were obtained from HyClone 
(South Logan, UT). Tissue culture flasks, petri dishes and cryotubes were purchased from 
Costar Corp. (Cambridge, England). Geneticin-G418 sulfate was purchased from GibcoBRL 
(Carlsbad, CA).  
3.1.3 Animal Experiments 
BALB/c mice were provided by Bilkent University Animal Housing Facility. All animal 
experiments were performed upon approval by and under the regulations of “Bilkent 
University Animal Ethical Committee”. 
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3.2 SOLUTIONS AND MEDIA 
3.2.1 Tissue Culture Solutions 
DMEM/RPMI-1640 growth media: 10% FBS, 1% penicillin/streptomycin, 1% nonessential 
amino acid were added and stored at 4oC. 
Freezing solution: 10% DMSO and 90% FCS were mixed freshly. 
Phosphate buffered saline (PBS): Stock solution (10XPBS) was prepared by dissolving 80 g 
NaCl, 2 g KCl, 17.8 g Na2HPO4.2H2O, and 2.4 g KH2PO4 in 1 lt ddH2O. Working solution 
(1XPBS) was prepared by dilution of 10XPBS to 1X with ddH2O. pH of the working solution 
was adjusted to 7.4. 
Geneticin (G418) sulfate: 500 mg/ml solution in ddH2O was prepared, sterilized by filtration 
and stored at -20°C (stock solution). 500 μg/ml was used as working solution for stable cell 
line selection and 250 μg/ml was used as working solution for maintenance of stable cell 
lines. 
Puromycin: 2 mg/ml solution in ddH2O. Sterilized by filtration and stored at -20°C (stock 
solution). 2 μg/ml was used as working solution for selection. 
3.2.2 Protein Extraction, Quantitation and Western Blotting Solutions 
Radio immuno-precipitation assay (RIPA) buffer: 150 mM NaCl, 50mM Tris-HCl pH 8.0, 
1% NP-40, 0.1% SDS and 1X protease inhibitor mix (Roche, Basel, Switzerland) were mixed 
in ddH2O. 
Bradford stock solution: 17.5 mg Coomassie brilliant blue was dissolved in 4.75 ml ethanol 
and 10 ml phosphoric acid and completed to 25 ml final volume with ddH2O. 
Bradford working solution: 1.5 ml Bradford stock solution was mixed with 0.75 ml 95% 
ethanol and 1.5 ml phosphoric acid and completed to final volume up to 25 ml with ddH2O. It 
was then filtered through whatman paper and prepared freshly. 
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Acrylamide-bisacrylamide solution: 29 g acrylamide and 1 g bisacrylamide were dissolved 
in 100 ml ddH2O and stored in the dark at 4oC (stock solution). 
10% Ammonium persulfate (APS): 0.1 g APS was dissolved in 1ml of ddH2O, prepared 
freshly. 
1.5 M Tris-HCl, pH 8.8: 54.45 g Tris base (18.15 g/100ml) was dissolved in ~150ml ddH2O. 
pH was adjusted to 8.8 with 1 N HCl. Final volume was completed to 300 ml with ddH2O and 
stored at 4°C. 
1 M Tris-HCl, pH 6.8: 12.14 g Tris base was dissolved in ~ 60 ml ddH2O, pH was adjusted 
to 6.8 with 1 N HCl. Final volume was completed to 100 ml with ddH2O and stored at 4°C. 
Coomassie brilliant blue solution: 100 mg Coomassie brilliant blue G-250, 50 ml 95% 
ethanol, and 100 ml 85% phosphoric acid was dissolved and final volume was completed to 1 
lt. It was then filtered through whatman paper and stored at 4°C. 
5X SDS-gel loading buffer: 5 g SDS, 25 mg bromophenol blue, 15.7 ml 1M Tris pH 6.8, 
21.8 ml glycerol (from 87% stock) were mixed and completed to 50 ml with ddH2O. Before 
use, β-mercaptoethanol was freshly added to a final concentration of 5% to reach 1% when 
mixed with protein samples. 
10X SDS-gel electrophoresis buffer: Per liter; 30.3 g Tris base, 144.0 g glycine, 10.0 g SDS 
were added. It was diluted to 1X for working solution and stored up to 1 month at 4°C. 
Semi-dry transfer buffer: 48 mM Tris base, 39 mM glycine, 0.037% SDS and 20% 
methanol were dissolved and final volume was brought to 1 lt. 
Wet transfer buffer: 3.03 g Tris and 14.4 g glycine was mixed with 1ml 10% SDS and 20% 
methanol and completed to final volume of 1 lt. For high molecular weight proteins methanol 
percentage was decreased by half. 
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10X Tris buffered saline (TBS): 30 g Tris base, 80 g NaCl and 2 g KCl were dissolved in 1lt 
of ddH2O and the pH was adjusted to 8 (stock solution). Diluted to 1X and pH was adjusted to 
7.6 with HCl just before use. 
TBS-Tween (TBS-T): 0.1% (v/v) Tween-20 was added into 1X TBS solution.  
Blocking solution: 5% (w/v) non-fat milk and 0.1% (v/v) Tween-20 were dissolved in 
1XTBS (prepared freshly). 
3.2.3 Immunoflourescence 
Fluorescein isothiocyanate (FITC): anti-mouse IgG (Sigma)  
DAPI (4', 6-diamidino-2-phenylindole): 0.1-1 μg/ml DAPI was prepared in ddH2O 
(working solution in ddH2O). 
2% paraformaldehyde: 2 g paraformaldehyde dissolved in 100 ml 1X PBS, pH 7.4 and 
stored in dark, at -20oC. 
PBS-TritonX-100 (PBS-T): 0.1% (v/v) Triton X-100 was added into 1X PBS. 
Blocking solution: 2% BSA (bovine serum albumin) was prepared in 1X PBS. 
3.2.4 Immunohistochemistry Solutions 
10 mM Citrate buffer: 2.94 g sodium citrate trisodium salt dihydrate was added to 1lt dH2O, 
and pH 6.0 was adjusted with NaOH. 
3% Hydrogen Peroxide: 10 ml 30% H2O2 was added to 90 ml dH2O. 
3.2.5 2D PAGE Solutions 
Rehydration/Sample Buffer: 10 ml of 8 M urea, 2% CHAPS, 50 mM dithiothreitol (DTT), 
0.2% (w/v) Bio-Lyte® 3/10 ampholytes, and Bromophenol Blue (trace) were mixed. 
Equilibration Buffer I: 20 ml of 6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), 20% 
glycerol, and 2% (w/v) DTT were mixed. 
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Equilibration Buffer II: 20 ml of 6 M urea, 2% SDS, 0.375 M Tris-HCl (pH 8.8), and 20% 
glycerol were mixed.  
Coomassie Brilliant Blue R-250 stain solution: 0.1% Coomassie Blue R-250 in 40% MeOH, 
10% acetic acid.  
Destain solution: 10% acetic acid, 40% methanol in dH2O. 
30% Glycerol Solution: Sterile 30% (v/v) glycerol. 30 ml glycerol was completed to a final 
volume of 100 ml by ddH2O. 
Nanopure Water: Sterile nanopure water. 
Iodoacetamide: Ultrapure grade of iodoacetamide. 
Overlay Agarose: 0.5% low melting point agarose was prepared in a mixture of 25 mM Tris, 
192 mM glycine, 0.1% SDS, and a trace of Bromophenol Blue. 
CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, a zwitterionic 
detergent. 
Bio-Lyte® 3/10: Ampholytes is a mixture of carrier ampholytes, pH 3 – 10. 
3.2.6 In Gel Protein Digestion Solutions 
Ammonium Bicarbonate (100mM): 395.3mg ammonium bicarbonate was dissolved and 
adjusted to a final volume of 50 ml by HPLC water, stored at room temperature. 
Ammonium Bicarbonate (100 mM) in 50% Acetonitrile (ACN): 395.3 mg Ammonium 
Bicarbonate, 25 ml HPLC ACN was brought up to 50 ml by HPLC water, stored at room 
temperature. 
Dithiothreitol (DTT) (10mM): 7.71 mg DTT was dissolved in 5 ml of 100 mM Ammonium 
Bicarbonate, freshly prepared. 
Iodoacetamide (IAA) (50mM): 56 mg iodoacetamide was reconstituted in 6.06 ml 
ammonium bicarbonate, freshly prepared. 
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Ammonium Bicarbonate (20mM) in 50% ACN: 10 ml 100 mM Ammonium Bicarbonate, 
15 ml HPLC water and 25 ml HPLC ACN, stored at room temperature. 
Ammonium Bicarbonate (40mM) in 10% ACN: 20 ml of 100 mM Ammonium Bicarbonate, 
5 ml of HPLC ACN and 25 ml HPLC water were mixed and stored at room temperature 
Acetic Acid (50mM): 144 μl Acetic Acid, up to 50 ml HPLC water, stored at room 
temperature. 
Trypsin Solution: 100 μl 50 mM acetic acid was brought up to 5 ml by 40 mM Ammonium 
Bicarbonate in 10% ACN, divided into 500 μl aliquotes and stored at -80°C. Each aliquote can 
undergo 5 freeze-thaw cycles. 
ACN (50%) /TFA (5%): 25 ml HPLC ACN and 2.5 ml TFA were mixed and brought up to 
50 ml by HPLC water. 
3.2.7 Matrix Preparation for MALDI Sample Spotting 
Matrix: 5-10 mg/ml α-Cyano-4-hydroxycinnamic acid (CHCA) was dissolved in ACN: 0.1% 
aqueous TFA mix, usually at 50:50, vortexed for about 1 min, spinned at 14000 rpm for 1 min 
to pellet the undissolved matrix, then supernatant was used for sample preparation. After use 
matrix was discarded.  
3.3 METHODS 
3.3.1 General Methods 
3.3.1.1 Recombinant SIP1 production 
Recombinant SIP1 protein was kindly provided by Emre Sayan (Leicester, UK). Briefly the 
first 360 amino acid part coding region of SIP1 (ZEB2) cDNA was cloned into pET101/D 
(Invitrogen, Carlsbad, CA) vector with an N-terminal 6-histidine tag. Recombinant protein 
was expressed in Escherichia coli (BL21) and purified under denaturing conditions using Ni–
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NTA resin (Qiagen, Hilden, Germany). Purified protein was then refolded and buffer 
exchanged to phosphate buffered saline (PBS) using NAP buffer exchange columns 
(Amersham, Piscataway, NJ). Finally, pure and folded recombinant protein was concentrated 
(0.5-1 mg/ml) using Centripreps (Millipore, Billerica, MA). 
3.3.1.2 Production of SIP1 Monoclonal Antibodies 
Recombinant SIP1 protein was injected into the peritoneal cavity of 8 to 10-week-old 
BALB/c mice at 3 week intervals. During the immunization period, antibody titer of mice sera 
was evaluated by indirect ELISA. Briefly, ELISA plates were coated by 100 ng of 
recombinant SIP1 protein in carbonate buffer (pH 9.6). Serially diluted mice sera were 
assessed for their immunoreactivity with SIP1 protein. Alkaline phosphatase conjugated goat 
anti-mouse IgG (Sigma-Aldrich, St. Louis, MO) was used as secondary antibody. The 
absorbance of the colorimetric reaction generated upon addition of the substrate para-
nitrophenyl-phosphate (Sigma-Aldrich, St. Louis, MO) was measured at 405 nm in an 
automated plate reader (Biotek Instruments, Winooski, UT). Three days after the final boost, 
fusion of mouse splenocytes and SP2/0 myeloma cells was performed as previously described 
(Celikkaya, Ciraci et al. 2007). Hybridoma supernatants were screened by aforementioned 
indirect ELISA, and hybridomas secreting anti-SIP1 antibodies were subjected to single cell 
subcloning. Antibody isotype was determined by ImmunoPure Monoclonal Antibody 
Isotyping Kit (Pierce, Rockford, IL).  
3.3.1.3 Production of 6D5 Monoclonal Antibody 
For production of mAbs that target HCC, sub-confluent HUH7 cells were harvested by 
scraping and injected into peritoneal cavity of 6-8 weeks old BALB/c mice. Following two 
more injections, mice were bled and their sera were assessed for immunoreactivity with 
HUH7 cells by using cell-ELISA assay. A final boost was given to mice showing highest 
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immunoreactivity, and after 3 days, these mice were sacrificed, their spleens were harvested, 
pooled and fused with SP2/0 mouse myeloma cells by using polyethyleneglycol. Cell-ELISA 
was performed to select positive clones, and hybridomas were sub-cloned by limiting dilution. 
Isotype of antibodies was determined by using Monoclonal Antibody Isotyping Kit (Pierce, 
Rockford, IL) according to manufacturer’s instructions. 
3.3.1.4 Western Blot Analysis 
Total cell lysates from cell lines were prepared in NP-40 lysis buffer [50 mM Tris-HCl pH 
8.0, 150 mM NaCl, 1% Non-idet P40 (v/v) and a cocktail of EDTA-free protease inhibitors 
(Roche)]. Protein content was measured by Bradford assay. After protein quantification, 
protein lysates were aliquoted into fresh tubes and, stored at – 80°C. Equal amounts of cell 
lysates were solubilized in 5X SDS gel-loading buffer with 5% β-mercaptoethanol (ME), 
denatured at 100°C for 5 min and incubated on ice for 2 min. After a quick spin, samples were 
loaded onto SDS-polyacrylamide gel. 10% (15-100 kDa range) resolving gel and 5% stacking 
gel was used in SDS-PAGE analysis of protein lysates. Mini Protean III (BioRad, Hercules, 
CA) vertical gel system was set up according to manufacturer’s instructions. After 
electrophoresis at 80 V for 20 min followed by 120 V 53 for 1-2 hr, proteins were transferred 
onto PVDF transfer membrane with 0.45 μm pore size (Millipore, Billerica, MA) by using 
Transblot-Semi Dry (BioRad, Hercules, CA) electroblotting apparatus according to the 
manufacturer’s instructions at 15 V for ~45 min. Membranes were blocked overnight with 5% 
dry milk in Tris-buffered saline (TBS) containing 0.1% Tween 20 (TBS-T). Undiluted 
hybridoma supernatants (6D5, 1C6, 6E5) were used as primary antibody. After washing three 
times with TBS-T, horseradish peroxidase (HRP)-conjugated goat anti-mouse IgG (Sigma) 
was used as secondary antibody at 1:5000 dilution for 1 hr. The membrane was washed 3 
times for 5 min in TBS-T solution at room temperature. After final wash, protein bands were 
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visualized using ECL Plus chemiluminescent substrate (Amersham). The chemiluminescence 
emitted was captured on X-ray film within 15 sec to 5 min exposure times. 
3.3.1.5 Immunofluorescence Assay 
Cells were grown on cover slips in 6 well plates. Phosphate buffered saline (PBS) was used in 
all washing steps. Cells were fixed in 2% paraformaldehyde in PBS and permeabilized in PBS 
containing 0.2 % Triton X-100. After blocking with 2% BSA-PBS, cover slips were incubated 
for 2 hr at room temperature in undiluted 6D5, 1C6 or 6E5 hybridoma supernatant. 
Fluorescein isothiocyanate (FITC) (Sigma) or Alexa fluor 488-(Invitrogen, Carlsbad, CA) 
conjugated anti-mouse IgG was used as secondary antibody at 1:200 dilution. Nuclei 
counterstaining was performed with 4',6-Diamidino-2-phenylindole (DAPI), cover slips were 
mounted on glass slides and examined under fluorescent microscope (Zeiss GmbH, 
Germany). Merged images were produced by using AxioVision image processing software 
(Zeiss GmbH, Germany). 
3.3.1.6 Immunohistochemical Staining 
For 6D5 and SIP1 immunostaining paraffin blocks containing liver tissues were cut at 4-5 μm 
thick and tissue sections were mounted on glass slides. For SIP1 immunostaining a total of 
123 tissues spotted on three tissue arrays were stained twice by both 1C6 and 6E5 mAbs. 
Tissue arrays included sections from kidney (22: tumor 18, normal 4), lung (17: tumor 14, 
normal 3), colon (16: tumor 12, normal 4), uterus (15: tumor 12, normal 3), esophagus (11: 
tumor 9, normal 2), liver (11: tumor 9, normal 2), breast (11: tumor 9, normal 2), rectum (10: 
tumor 9, normal 1) and stomach (10: tumor 9, normal 1) tissues. After deparaffinization in 
xylene and rehydration in graded alcohol series, glass slides were immerged in 10 mM citrate 
buffer, pH 6.0 and transferred into microwave for 15 min for antigen retrieval. Endogenous 
peroxidase activity was blocked by incubation of slides in 0.1% H2O2 for 30 min. PBS was 
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used in all washing steps. Tissue sections were incubated for 2 hr with primary antibodies, 
6D5 hybridoma supernatant, Ki-67 (DakoCytomation, CA, USA) or AFP (Neomarkers, 
Fremont, CA) and after washing, universal staining kit (LabVision) was used according to 
manufacturer recommendations. Aminoethylcarbazol (AEC) or 3,3'-diaminobenzidine (DAB) 
were used as chromogen, and the slides were counterstained using Mayer’s hematoxylin. 
Cytoplasmic staining of hepatocytes was assessed in entire tissue samples and 
immunoreactivity was classified into four categories. Positively stained cells were scored as 
either diffusely positive (D: 50-100 % of the positively stained area), moderately positive (M: 
5-50 % of the area), focally positive (F: 1-5% of the area) and negative (N: completely 
negative). The same scoring was applied for staining with AFP antibody. As for Ki-67 
evaluation, samples showing a nuclear staining of more than 10% were assessed as positive, 
lesser staining intensity was scored as negative. Staining was performed in triplicate for both 
antibodies. For SIP1 immunoreactivity, the sections were evaluated by light microscopic 
examination and the intensity of immunostaining in each section was assessed independently 
by two observers. The intensity of total SIP1 staining on each sample was scored as 
previously described with a slight modification (Chen, Hsieh et al. 2006). Briefly the staining 
intensity was graded relatively based on the following scales: 0, 1, 2, and 3 for negative, 
weak, moderate and strong staining, respectively. An average score was reached as the final 
score for each tissue with multiple samples. According to the final immunostaining scores, the 
tissues were classified into four groups: negative group (score 0–0.40), weak staining group 
(score 0.5–1.4), moderate staining group (scores 1.5–2.4), and strong staining group (scores 
2.5–3). (-), (+), (++) and (+++) designations were used for these four groups, respectively. 
The staining in nuclei and cytoplasm was determined separately on each specimen. 
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3.3.2 Tissue Culture Techniques 
3.3.2.1 Cell Lines 
Thirteen hepatoma (HUH7, FOCUS, Mahlavu, Hep40, Hep3B, PLC/PRF/5, SK-Hep1, 
Snu182, Snu387, Snu398, Snu423, Snu449 and Snu475) and one hepatoblastoma (HepG2) 
cell lines were cultured as described previously (Celikkaya, Ciraci et al. 2007). For 
experiments where a defined number of cells were to be seeded, cell counting was performed. 
Following trypsinization, cells were resuspended in culture medium and counted manually 
with a hemocytometer. 
3.3.2.2 Thawing Cryopreserved Cells 
One vial of the frozen cells from the liquid nitrogen tank was taken and immediately put into 
ice. The vial was left for 1 min on the bench to allow excess nitrogen to evaporate and then 
placed into 37oC water bath until the external part of the cell solution was thawed (takes 
approximately 1-2 min). The cells were directly poured into a 15ml sterile tube containing 
10ml cold fresh medium. The cells were centrifuged at 1500 rpm at 4oC for 5 min. 
Supernatant was discarded and the pellet was resuspended in 10ml 37oC culture medium to be 
plated into 100mm dish. After overnight incubation in a humidified incubator at 37oC 
supplied with 5% CO2, culture mediums were refreshed. 
3.3.2.3 Growth Conditions of Cell Lines 
Focus, Hep40, Hep3B, Hep3B-TR, HepG2, HUH7, Mahlavu, PLC/PRF/5, SK Hep1 cells 
were cultured in low-glucose DMEM supplemented with 10% FBS, 100U/ml Penicillin-
Streptomycin, and 0.1 mM non-essential amino acids (HyClone, Utah, USA). SNU387, 
SNU398, SNU423, SNU449, SNU475 cells were cultured in RPMI1640 medium 
supplemented with 10% FBS, 100 U/ml Penicillin-Streptomycin, 0.1 mM non-essential amino 
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acids (HyClone, Utah, USA). The growth medium was aspirated and the cells were washed 
once with 1XPBS. Trypsin was added to the flask to remove the monolayer cells from the 
surface. The fresh medium was added and the suspension was pipetted gently to disperse the 
cells. The cells were transferred into either fresh petri dishes or fresh flasks using different 
dilutions (from 1:2 to 1:10) depending on requirements. All media and solutions used for 
culture were kept at 4°C (except stock solutions) and warmed to 37°C before use.  
3.3.2.4 Cryopreservation of Cell Lines 
Exponentially growing cells were harvested by trypsinization and neutralized with growth 
medium. The cells were counted and precipitated at 1500 rpm for 5 min. The pellet was 
suspended in a freezing solution (10%DMSO, 20%FCS and 70%DMEM for adherent cells) at 
a concentration of ~4x106cells/ml. 1ml of this solution was placed into 1ml screw capped 
cryotubes. The tubes were first frozen at -20°C for 0.5-1 hr and then left at -80°C overnight. 
The next day, the tubes were transferred into the liquid nitrogen storage tank. 
3.3.2.5 Crude Total Protein Extraction 
Adherent monolayer cells (both stable and parental cells) were grown to 80% confluency. For 
the analysis of proteins, cells were collected by trypsinization. Cells were collected by 
scraping after washing twice with ice-cold PBS to remove any serum residue. Volume of the 
dry cell pellet was estimated and twice that volume of lysis buffer was pipetted onto the 
pellet. For nuclear proteins RIPA lysis buffer [150 mM NaCl, 50 mM Tris-HCl pH 8.0, 0.5% 
sodium deoxycholate, 1 % NP-40, 0.1% SDS and 1X Complete Protein Inhibitor mix (Roche 
Diagnostics, Mannheim, Germany)] was used, and for cytoplasmic and membrane proteins 
NP-40 lysis buffer [50 mM Tris pH 8.0, 150 mM NaCl, 1X protease inhibitor cocktail 
(Roche) and 1.0% NP-40] was used. Complete lysis was achieved by pipetting of crude cell 
lysates several times and by incubating the lysates on ice for 30 min and with continuous 
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agitation by vortexing at 5 min intervals. Then, the lysate was centrifuged at 10000 rpm for 30 
min. Total cell protein was collected as supernatant.  
3.3.2.6 Quantification of Proteins 
After the cell lysates were prepared, their concentrations were detected by Bradford assay. 
Briefly, 2 μl of the samples were diluted with 98 μl dH2O and then 900 μl of Bradford 
working solution was added to the samples and mixed well, as described in Table 3.1. 
Immediately, the protein amounts of the samples were measured at 595 nm versus blank 
reagent (NP-40 lysis buffer was used as blank). Known concentrations of BSA were prepared 
according to Table 3.2 as a standard. After reading at 595 nm, samples and standard values 
were plotted; unknown concentrations were calculated from the standard curve. 
 
Table 3.1 Protein sample preparation for Bradford assay. 
 Tube no 
 1 2 3 4 5 6 
Sample (µl) 0 2 2 2 2 2 
ddH2O (µl) 98 98 98 98 98 98 
Bradford (µl) 900 900 900 900 900 900 
Lysis buffer (µl) 2 - - - - - 
 
Table 3.2 BSA dilutions for standard curve plot. 
 Tube no 
 1 2 3 4 5 6 7 8 
Sample (µl) 0 2.5 5 7.5 10 12.5 15 20 
ddH2O (µl) 100 97.5 95 92.5 90 87.5 85 80 
Bradford (µl) 900 900 900 900 900 900 900 900 
 
3.3.2.7 Cell Lines, Tissues Cell Lines, Tissues and siRNA Transfections 
Wild-type mouse SIP1 expressing squamous epidermoid carcinoma cell line A431/WTSIP1 
with Tet-on doxycyline-inducible SIP1 expression was previously described (Mejlvang, 
Kriajevska et al. 2007). HCC cell line SK-HEP-1 and colorectal carcinoma cell lines SW480 
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and SW620 were maintained in DMEM supplemented with 10% fetal bovine serum, 100 IU 
penicillin, 100 μg streptomycin and nonessential amino acids. Multiple Tumor Tissue arrays 
were purchased from BioChain Institute, Inc. (Hayward, CA). Cells were collected 48 hr after 
transfection and processed for western blotting. 
3.3.2.8 SIP1 Quantitative Real-Time PCR 
SIP1 mRNA expression in colon cancer cell lines SW620, SW480 and HCC cell line SK-
HEP-1 was determined by quantitative real-time PCR as described previously (Avci, Konu et 
al. 2008). The expression of SIP1 in cell lines was measured using ∆∆Ct method and 
normalized to GAPDH gene. The threshold cycle of SIP1 cDNA in SW480 cell line, which 
showed the lowest expression was set to 1 and relative expression values were plotted as fold 
changes. 
3.3.2.9 6D5 mAb Binding Assay (Epitope Mapping) 
A protein microarray (Source BioScience ImaGenes, Berlin, Germany) PVDF membrane (22 
x 22 cm) presenting 2 x 27,648 in situ expressed human testis proteins was used for screening 
of 6D5 mAb targets (epitopes). The protein microarray membrane was placed in a plastic box 
and rinsed in 70% ethanol at room temperature. Then membrane was washed 2x (~2min) with 
ddH2O in order to remove traces of ethanol. After then membrane was rinsed with 25ml TBS-
T, and washed by shaking them 3x for 10 min at room temperature. Then membrane was 
briefly rinsed 2x at room temperature in TBS in order to remove traces of TBS-T. Membrane 
was socked for 2 hr at room temperature in blocking solution. After then blocking solution 
was removed and the 6D5 mAb, as primary antibody, was added into plastic box, agitated 
overnight at 4°C. Second day, primary antibody was discarded, and membrane was washed 3x 
15 min at room temperature in TBS-T. Subsequently membrane was incubated with 
horseradish peroxidase (HRP)-conjugated anti-mouse (Sigma-Aldrich, St. Louis, MO) 
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secondary antibody at 1:5000 dilution in blocking solution for 1 hr at room temperature. 
Protein spots were visualized using Super Signal West Dura chemiluminescent substrate 
(Pierce, Rockford, IL). The chemiluminescence emitted was captured on X-ray film within 15 
sec to 5 min exposure times, and films were scanned (Perfection V750 Photo, Epson, Long 
Beach, CA), then images were merged, and image analysis was performed using an image 
software (Photoshop CS4, Adobe Systems Inc., San Jose, CA). 
3.3.2.10 6D5 Immunoprecipitation with HUH7 Cell Lysate  
Protein G beads (100 μl, 50%) (Pierce) were added to each micro-centrifuge tube. The beads 
were pelleted at <2000 rpm for 30 seconds and washed in ice cold PBS (1 ml x3) once. 6D5 
antibody sera (100 µl) were combined with HUH7 lysate (30 µl) in a tube and the mixture 
was rotated for 1 hr at 4°C. 100 µl of 50% protein G-agarose slurry were mixed with the mAb 
and cell lysate mixture, and rotated for 24 hr at 4 °C. Monoclonal antibody culture medium 
and isotype control antibodies (Invitrogen) were used as control antibodies to evaluate false 
positivity. The beads were washed with cold PBS (1 ml x3) at 4°C for 30 min under rotation. 
The agarose beads tubes were centrifuged for 10 sec at 14000 rpm and excess PBS was 
removed with disposable transfer pipettes. Half of beads were resuspended in gel-loading 
buffer for one dimentional (1D) electrophoresis. The other half of beads was resuspended in 
500 µl of IEF sample rehydration buffer (Bio-Rad, Hercules, CA) for 2D PAGE running at 
room temperature for 30 min and gently swirled to maintain the beads in suspension. The 
supernatant was collected, transferred to a new tube, and centrifuged at 14000 rpm for 2 min.  
3.3.2.11 Two-dimensional PAGE and Western Blotting 
For 2D PAGE analysis of HUH7 proteins, a modified method was used as described before 
(Fang, Yi et al. 2006). Extracted HUH7 cell lysates were dissolved in the standard SDS 
PAGE buffer containing 2% SDS and 5% ME and boiled for 2 min. Solubilized proteins were 
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precipitated with cold acetone and washed with trichloroacetic acid and ether/ethanol. The 
final dried protein precipitate was dissolved in the 8 M urea containing IEF sample buffer 1 
obtained from Bio-Rad. Adding a small amount of 0.1 M NaOH to the sample buffer to bring 
the pH to 8 resulted in improved solubilization of proteins. This pH adjustment did not have 
any noticeable effect on IEF and significantly increased the amount and intensity of protein 
spots seen in the stained gels. Concentrated supernatant from cell lysate was replaced by a 
rehydration solution containing urea, CHAPS, DTT, and carrier ampholytes. The tubes were 
vortexed to ensure that the pellet had dissolved in the rehydration solution and 125 ml of the 
sample was pipetted into a clean rehydration tray (Bio-Rad). Seven-centimeter precast IPG 
strips with a pH range of 3–10 (Bio-Rad) were placed gel-side down over each sample, 
covered with mineral oil, and allowed to sit for approximately 16 hr while they rehydrated. 
Strips were then transferred to a focusing tray and placed in a programmable IEF unit 
(Protean II IEF cell, Bio-Rad, CA). IEF was performed at 20°C with a 20-min linear ramp to 
250 V, followed by a 2-hr linear ramp to 4000 V, and finally a 10 000 V hr rapid ramp to 
4000 V (limit 50 µA/strip). When focusing was complete, strips were stored immediately at 
80°C in sterile tubes. Focused 1D strips were thawed and equilibrated in a buffer containing 
urea, Tris, SDS, glycerol, DTT and iodoacetamide, with gentle shaking for a total of 20 min. 
Equilibrated strips were placed on a 7x7 cm 12.5% resolving gel for separation, with a 
standard-soaked electrode wick with a molecular weight marker (Precision Plus Unstained 
Standards, Bio-Rad). Glass plates were spaced 1 mm apart and loaded into gel cassette 
immersed in SDS running buffer. Electrophoresis was carried out in a vertical gel apparatus 
(Mini-PROTEAN3, Bio-Rad, CA) with the protocol steps as in Table 3.3, and one gel was 
fixed immediately in a solution containing methanol, acetic acid. Other 2D PAGE gel with 
separated proteins were transferred to PVDF membranes for western blotting as described 
before (Eckerskorn, Strupat et al. 1997). Proteins were separated in SDS-PAGE gels identical 
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to those used for 2D-PAGE. Gels were stained with Coomassie, SYPRO Ruby or silver, and 
corresponding gel spots with 2D western blots, containing proteins of possible target of 6D5, 
were cut from the gel for the protein identification by MALDI.  
 
 
Table 3.3 IPG strips (7 cm) isoelectric focusing. 
 Voltage Time Volt-Hours Ramp 
Step 1 250 
 
20 min ------ Linear 
Step 2 4,000 
 
2 hr 
 
----- Linear 
Step 3 4,000 
 
----- 10,000 V-hr Rapid 
Total  5 hr 14,000 V-hr  
 
3.3.2.12 Gel Staining with Coomassie  
Coomassie brilliant blue R-250 staining was performed as previously described before 
(Wilson 1983). After electrophoresis, the gels were stained for 2 hr in Coomassie staining 
solution with slow shaking, and washed overnight in washing solution containing 10% (v/v) 
acetic acid and 50% (v/v) methanol Then staining solution was replaced with destaining 45 
solution for 30 min to remove bulk of the excess stain and then the gel was transferred into 
the destaining solution. Destaining solution was changed twice a day until the background 
was clear. The gels were rinsed three times with ddH2O before the image acquisition. 
3.3.2.13 Gel Staining with Silver  
Silver staining was performed as previously described (Giulian, Moss et al. 1984). The gel 
was immersed in destain solution for 30 min with gentle shaking. After 30 min Destain was 
discarded and cross-linking solution was added and again shaken slowly for 30 min. Cross-
linking solution was poured off and the gel was washed with ddH2O several times over 2 hr or 
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the gel was placed into 2 lt of ddH2O for overnight storage. The next morning, the gel was 
washed in fresh ddH2O for 30 min. The gel was incubated in DTT (dithiothreitol) solution 
with gentle shaking for 30 min. DTT solution was removed and silver nitrate solution was 
added and again shaken gently for 30 min. The gel was washed with ddH2O for two or three 
times and washed with developing solution for once. Then fresh developing solution was 
added. Staining had been obtained within 5-10 min. When the desired staining level was 
reached, development was stopped by replacing the development solution with destain 
solution. The gels were rinsed three times with ddH2O before the image acquisition. 
3.3.2.14 Gel Staining with SYPRO Ruby 
The SYPRO Ruby staining was used as previously described (Berggren, Chernokalskaya et 
al. 2000). SYPRO Ruby (BioRad) is a commercial ready-to-use solution. Two dimentional 
gels were fixed using 7% acetic acid and 10% ethanol for 1 hr. Gels were then placed into a 
tray containing SYPRO Ruby protein gel stain for overnight with continuous gentle agitation. 
The gels were destained using 7% acetic acid and 10% ethanol for 20 min. Finally, the gels 
were rinsed three times with ddH2O before the image acquisition. 
3.3.3 Protein Analysis by Mass Spectrometry 
Protein spots were excised from the gel before in-gel tryptic digestion (Shevchenko, Wilm et 
al. 1996) and the resulting peptides were mixed with matrix and spotted on the target plate to 
analyze by MALDI-TOF mass spectrometry.  
3.3.3.1 In-Gel Trypsin Digestion (Coomassie and SYPRO stained gel pieces) 
For Coomassie or SYPRO stained gel pieces, in-Gel Trypsin Digestion Procedure was carried 
out as described before (Gobom, Nordhoff et al. 1999). Target bands or spots excised from 1D 
or 2D gels were cut into 1 x 1 mm pieces and placed in 1.5 ml tube. Gel pieces were rinsed 
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with 300 μl HPLC water for 15 min at room temperature. In tubes 300 μl HPLC ACN were 
added and washed on shaker for 15 min at room temperature. Supernatants were discarded. 
Gel pieces were washed with 300 μl of 100 mM Ammonium Bicarbonate for 15 min at room 
temperature on shaker. Supernatants were discarded. 300 μl of 100 mM Ammonium 
Bicarbonate in 50% ACN were added and washed on shaker for 15 min at room temperature. 
Supernatants were discarded. 100 μl HPLC ACN was added and washed on shaker for 5 min 
at room temperature. Supernatants were discarded. Gel pieces were dried in a vacuum 
concentrator (Univapo 100 ECH, UniEquip GmbH, Germany) for 5 min. 50 μl of 10 mM 
DTT was added and incubated at 60°C for 1 hr. Supernatants were discarded. 50 μl of 50 mM 
IAA was added and incubated in dark for 30 min at room temperature. Supernatants were 
discarded. Gel pieces were washed on shaker with 300 μl of 100 mM Ammonium Bicarbonate 
for 15 min at room temperature. Supernatants were discarded. Gel pieces were washed on 
shaker with 300 μl of 20 mM Ammonium Bicarbonate in 50% ACN for 15 min at room 
temperature. Supernatants were discarded. 100 μl HPLC ACN was added and washed on 
shaker for 5 min at room temperature. Supernatants were discarded. Gel pieces were dried in a 
vacuum concentrator centrifuge for 5 min. 20 μl trypsin solution was added and incubated for 
1 hr at room temperature. 40 mM Ammonium Bicarbonate in 10% ACN was added to 
completely cover the gel pieces. Gel pieces were incubated at 37°C overnight. 150 μl HPLC 
ddH2O was added on shaker to wash the pieces for 10 min at room temperature. Supernatants 
were removed and placed in a 0.5 ml tube. The gel pieces were extracted with 50 μl of 50% 
ACN/5% TFA for 60 min twice at room temperature. Supernatant (extracts) all were collected 
and pooled and dried in a vacuum concentrator. 
3.3.3.2 Matrix Preparation and Samples Spotting on the Target Plate 
Three µl of a 10 mg/ml of α-Cyano-4-hydroxycinnamic acid (CHCA) matrix dissolved in 
50% ACN and 0.1% TFA solution was mixed with 1 µl of an approximately 10 pmol/µl 
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sample and 1 µl of this mixture was spotted on the target plate and air-dried by the “dried 
droplet” technique (Karas and Hillenkamp 1988). 
3.3.3.3 MALDI-TOF Mass Spectrometry Analysis  
For identification of 6D5 targets, gel spots containing proteins of interest were excised from 
one or two-dimensional gels stained with either Coomassie or Silver or SYPRO, and 
submitted to the proteomics laboratories at Ankara University Biotechnology Institute and 
Marmara University Chemical Engineering Department (Ankara and Istanbul, Turkey) for 
peptide mass analysis. Samples were analyzed using the MALDI-LR (Waters/ Micromass UK 
Ltd., Manchester, UK) instrument. After purification/concentration of the tryptic peptides 
MALDI-TOF peptide mapping was carried out. Spectra were generated using a pulsed 
nitrogen gas laser (337 nm) in positive linear mode, with a low mass gate of 10000 Da. The 
accelerating voltage was 15 kV. External calibration was performed using a peptide mixture 
(ADH, BSA) as molecular weight standards for purposes of mass correction. Three replicated 
measurements were performed on each sample. TOF-MS spectra were generated from the 
sum of 100-200 laser pulses and mass determinations were done by finding the peak centroid 
of a smoothed signal (by Savitzky-Golay algorithm) after background subtraction. Spectra 
were obtained randomly over the surface of the matrix spot at laser intensity determined by 
the operator. A S/N ratio of threshold of 10 was used for peak selection. Peak masses and 
intensities of TOF spectra were detected and collected in the “enhance all” modus and 
charged ions of peptides were chosen manually for product ion analysis. Product ion spectra 
(tandem MS) were acquired with collision energies optimized for each peptide to obtain an 
effective fragmentation pattern with 10% intensity of the residual precursor ion. Data were 
blasted against the sequence databank using ProteinLynx Global server 2 software 
(Waters/Micromass UK Ltd., Manchester, UK). Data also were searched by the tandem mass 
spectrum database matching tool Mascot (http://www.matrixscience.com). Positive protein 
42 
 
identifications were assigned on the basis of combined ion scores (calculated by the software) 
that exceeded the calculated deprecated protein identification threshold. 
3.3.4 Statistical Analysis 
For comparison of two groups with equal sample numbers, built-in t-test statistics was used in 
MS Excel (using two-sample with unequal variance, with a two tailed distribution mode).  
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4 RESULTS 
4.1 Expression profile of monoclonal antibodies 
4.1.1 SIP1 Monoclonal Antibodies (6E5, 1C6) Expression Profile 
Two mAbs, clones 1C6 and 6E5 were obtained by immunizing BALB/c mice with a partial 
human SIP1 recombinant protein (aa 1-360). The isotypes of antibodies were IgG2a and 
IgG1, respectively. 
4.1.1.1 Monoclonal Antibodies 1C6 and 6E5 Detect Overexpressed SIP1 
The specificity of these new SIP1 mAbs were also validated in the inducible cell line system 
A431 containing mouse WTSIP1. By using both antibodies in immunofluorescence assay, we 
detected nuclear expression of SIP1 in these cells maintained in the presence of doxycycline 
for 24 hr (Fig. 4.1). These results showed that the new SIP1 mAbs are specific and able to 
detect SIP1 in endogenous levels and when overexpressed. 
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Figure 4.1 SIP1  induced expression detected by 1C6 and 6E5 mAbs. A431/WTSIP1 cells 
maintained in 2 µg doxycycline for 24 hr and stained with 6E5 mAb displayed nuclear SIP1 
expression (first row), whereas no staining was observed in un-induced cells with the same 
antibody (second row). 
 
4.1.1.2 Cytoplasmic Expression of SIP1 in Tissue  
Next, the tissue expression pattern of SIP1 protein was analyzed by staining formalin-fixed 
and paraffin-embedded tissue arrays with mAbs 1C6 and 6E5. 22 normal and 101 tumor 
tissues were examined by immunohistochemistry and all samples displayed similar reactivity 
upon staining by both clones. The SIP1 immunostaining pattern of tissues was summarized in 
Table 4.1. No immunoreactivity was observed in tissue arrays stained with mouse IgG1 and 
IgG2a isotype control antibodies.  
The majority of tissues displayed cytoplasmic staining of SIP1 and nuclear expression of SIP1 
was observed only in 6 cases consisting of one normal and one tumor tissues of rectum and 
four normal colon samples.  
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Table 4.1 Immunohistochemistry results of SIP1 expression in human tissues 
Tissue (n=123) 
SIP1 Expression 
(Mean staining intensity in positive cases) 
Cytoplasm Nucleus SIP1-positive structure 
Kidney  
Tumor (n=18) 
Normal (n=4) 
 
+++ (17/18) 
++ (4/4) 
 
- 
- 
 
Tumoral cells 
Proximal-distal tubules 
Lung  
Tumor (n=14) 
Normal (n=3) 
 
+ (10/14) 
- 
 
- 
- 
 
Tumoral cells 
Surfactant ++(3/3) 
Breast  
Tumor (n=9) 
Normal (n=2) 
 
+ (5/9) 
- 
 
- 
- 
 
Tumoral cells 
- 
Uterus  
Tumor (n=12) 
Normal (n=3) 
 
+ (5/12) 
- 
 
- 
- 
 
Tumoral cells 
- 
Liver  
Tumor (n=9) 
Normal (n=2) 
 
++ (9/9) 
+++ (2/2) 
 
- 
- 
 
Tumoral cells 
Hepatocytes 
Stomach  
Tumor (n=9) 
Normal (n=1) 
 
+ (4/9) 
+++ (1/1) 
 
- 
- 
 
Tumoral cells 
Glandular cells 
Colon  
Tumor (n=12) 
Normal (n=4) 
 
+ (4/12) 
++ (4/4) 
 
- 
+ (4/4) 
 
Tumoral cells 
Surface epithelium 
Rectum  
Tumor (n=9) 
Normal (n=1) 
 
+ (7/9) 
++ (1/1) 
 
++ (1/9) 
++ (1/1) 
 
Tumoral cells 
Surface epithelium 
Esophagus  
Tumor (n=9) 
Normal (n=2) 
 
+ (5/9) 
++ (2/2) 
 
- 
- 
 
Tumoral cells 
Squamous epithelium 
(-): negative, +: weak, ++: moderate, +++: strong staining  
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4.1.1.3 Differential Expression of SIP1 in Human Tumors 
SIP1 is overexpressed in tumors of the kidney, lung, breast and uterus. 1C6 and 6E5 
antibodies stained both proximal and distal tubules of kidney, yet the reactivity of the latter 
was more intense. Compared to the tubular epithelium-restricted expression of SIP1 in normal 
kidney, SIP1 was extensively expressed in kidney tumors. Out of 18 tumors, 17 clear cell 
carcinomas displayed strong cytoplasmic staining with both antibodies (Fig. 4.2 A-B), and 
one transitional cell carcinoma case remained negative. Relative to their normal tissues, which 
failed to display SIP1 expression, 71% of lung, 56% of breast and 42% of uterus tumors 
showed cytoplasmic SIP1 positivity, yet with a weak intensity (Fig. 4.2 C-H).  
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Figure 4.2 Increased expression of SIP1 in kidney, lung, breast and uterus tumors. 
Representative photographs show increased SIP1 expression in tumors relative to their normal 
tissues as detected by immunohistochemistry performed by both antibodies. (A) Distal tubule 
staining in normal kidney, (B) clear cell renal carcinoma, (C) normal uterus, (D) 
adenocarcinoma of the uterus, (E) normal lung with non specific surfactant staining, (F) 
squamous cell carcinoma of the lung, (G) normal breast, (H) breast ductal carcinoma. (−): 
negative, +: weak, ++: moderate, +++: strong staining intensity. (Scale bars: 50 μm) 
 
4.1.1.3.1 Downregulated Cytoplasmic SIP1 in Most of the Human Tumors 
The cytoplasm of all 9 HCC cases displayed a moderate intensity of SIP1 expression, which 
could not reach however the strong staining pattern of SIP1 in normal hepatocytes and tumor-
adjacent cirrhotic tissues (Fig. 4.3 A, B). Eight of nine stomach adenocarcinomas were 
weakly positive for SIP1 expression, a pattern far beyond the intense SIP1 staining of 
glandular cells of normal stomach (Fig. 4.3 C, D). Apical crypt epithelia of 4 normal colon 
samples displayed cytoplasmic staining with both antibodies with moderate intensity, and a 
faint nuclear SIP1 expression was also observed in these cells. However, only 4 of 12 colon 
tumors were weakly positive for cytoplasmic SIP1 (Fig. 4.3 E, F). In tissue arrays, only one 
normal rectum sample was available, and lumen-facing epithelial cells of this tissue were 
found to express SIP1 mainly in their nuclei and to a lesser extent in their cytoplasm. 
Irrespective of its cellular localization, SIP1 expression was of moderate to strong intensity in 
normal rectum. On the contrary, 78% of rectum tumors were stained, but with weak 
immunoreactivity (Fig. 4.3 G, H). The dominant cytoplasmic staining pattern of these cancer 
tissues was accompanied by moderate nuclear staining in only one case, which was the tumor 
with most advanced stage among others. Tumor cells of 5 squamous cell carcinoma of the 
esophagus expressed SIP1, yet with a weaker intensity than squamous epithelium of normal 
esophagus, which was stained with moderate intensity by both antibodies (Fig. 4.3 I, J). 
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Figure 4.3 Reduced expression of SIP1 in liver, stomach, colon, rectum and esophagus 
tumors. Representative photographs show decreased SIP1 expression in tumors with respect 
to their normal tissues. (A) Normal liver, (B-right) hepatocellular carcinoma (HCC) of the 
liver and (B-left) the adjacent cirrhotic tissue, (C) normal stomach gland cells, (D) 
adenocarcinoma of the stomach, (E) normal colon surface epithelium, (F) adenocarcinoma of 
the colon, (G) normal rectum surface epithelium, (H) adenocarcinoma of the rectum, (I) 
normal esophagus squamous epithelium, (J) squamous cell carcinoma of the esophagus. +: 
weak, ++: moderate, +++: strong staining intensity (scale bars: 50 μm). 
 
4.1.1.3.2 Cytoplasmic SIP1 Immunoreactivity in Tumor Cell Lines  
Cytoplasmic SIP1 expression in the majority of human carcinomas prompted us to validate 
this observation in two colon cancer cell lines (SW620 and SW480) and one HCC cell line 
(SK-HEP-1). Subcellular fractionation was done and the presence of SIP1 protein was 
analyzed by western blotting. A protein band with strong intensity at the expected size (190 
kDa) of SIP1 was observed in the nuclear fraction of the invasive HCC cell line SK-HEP-1 
(Fig 4.4 A). Weaker protein bands of the same size also appeared in the cytosolic fraction of 
SK-HEP-1, and in both cytosolic and nuclear fractions of SW620 and SW480 cells. However, 
SIP1 expression was barely detectable in total cell lysates. Besides, SIP1 antibody 
immunoreactive bands at about 120 kDa and lower molecular weights were also observed in 
the nuclear extracts and total cell lysates of all 3 cell lines (Fig 4.4 A). These results were in 
accordance with real-time quantitative PCR data in which SK-HEP-1 was the cell line with 
most abundant SIP1 transcript (Fig. 4.4 B).  
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Figure 4.4 Nuclear and cytoplasmic expression of SIP1 protein in cell lines. (A) A strong 
SIP1 expression at 190 kDa in the nuclear fraction of SK-HEP-1 cells is seen in western 
blotting experiment with clone 1C6 mAb. The antibody also detects bands with lower 
molecular weight proteins in nuclear (N) and total cell lysates (T) of all 3 cell lines. SIP1 
expression is more abundant in the cytoplasmic (C) but not nuclear extracts of SW480 and 
SW620 cells. SK-HEP-1 cells express similar pattern for the cytoplasmic SIP1 
immunoreactivity. (B) SIP1 transcripts showed the highest SIP1 expression in SK-HEP-1 cell 
line with qRT-PCR. SIP1 transcript levels in SK-HEP-1 and SW620 cells are represented as 
fold changes with respect to SW480 reference cell line. 
 
Overall, our results indicated that SIP1 was widely expressed in most normal human tissues 
that we examined, with moderate to strong intensities, and the overexpression of SIP1 was 
confined only to a restricted group of human tumors.  
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4.1.2 6D5 Monoclonal Antibody  
4.1.2.1 Generation of 6D5 Monoclonal Antibody 
In order to explore proteins differentially expressed in HCC, we immunized mice with HUH7 
cells. The heterogeneous characteristics of HUH7 cells make these cells ideal immunogen for 
the identification of novel markers for liver tumors, as well as the characterization of liver 
precursor cells involved in hepatocellular carcinogenesis. For instance, we isolated two 
isogenic clones from this cell line, which kept tumor cell proliferative capacity and underwent 
senescence in standard culture conditions, respectively (Chu, Ishizawa et al. 2002; Ozturk, 
Erdal et al. 2006). Out of 127 clones generated by cell fusion, 18 were assessed as positive by 
cell-ELISA, and supernatants of these clones were evaluated in western blot and 
immunofluorescence experiments. We selected 6D5 antibody for further studies to investigate 
its potential as a diagnostic and predictive biomarker. The isotype of clone 6D5 mAb was 
found to be IgG3 (κ). 
4.1.2.2 6D5 Recognizes Differentially Expressed Proteins in HCC Cell Lines 
We first analyzed the immunoreactivity of 6D5 antibody with whole cell lysate of HCC cell 
lines. Positive protein bands were observed in three separate western blot experiments (Fig 
4.5 A, B, C). Cell lines derived from undifferentiated and invasive tumors (SNU series, SK-
Hep1) seemed to express 6D5 ligands stronger than differentiated cell lines (HUH7, HepG2). 
However, no other correlation could be established between the protein expression patterns 
and phenotypic characteristics of cell lines.  
Another interesting finding was the differential protein expression in two isogenic cell lines, 
namely Hep3B and Hep3B-TR (Fig. 4.5 C). These cell lines have been described elsewhere, 
and Hep3B-TR cells differ from Hep3B cells by their resistance to the growth inhibitory 
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effect of TGF-beta in cell culture (Wright, Kreikemeier et al. 2007). In the same study, it has 
also been proven that Hep3B-TR cells are devoid of TGF-β Receptor Type II expression.  
Proteins were also found to be abundantly expressed in all studied cell lines, since 6D5 
detected ligands in western blots performed with total protein content as low as 1 μg/lane. 
 
 
Figure 4.5 6D5 immunoreactivity in HCC cell lines. Target proteins appear to be expressed 
stronger in poorly differentiated cell lines in three separate western blot experiments. 
 
4.1.2.3 6D5 Stained the Cytoplasm of HCC Cell Lines 
Next, we visualized the cellular localization of 6D5 antigens by immunofluorescence 
microscopy. 6D5 stained the cytoplasm of immunogen HUH7 and other HCC cell lines as 
well. The strong intensity of the fluorescent signal verified our observation that proteins 
recognized by this antibody were abundantly expressed in HCC cell lines (Fig. 4.6). 
Based on the above in vitro data, we planned to explore immunohistological staining pattern 
of 6D5 antibody in human liver tissue samples to examine whether 6D5 proteins were 
differentially expressed in distinct clinico-pathological settings. 
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Figure 4.6 Cellular localization of 6D5 mAb targets. Examination of HCC cell lines by 
immunofluorescence microscopy revealed strong cytoplasmic fluorescent signals. 
 
4.1.2.4 6D5 Antibody Failed to React with Non-Tumoral Liver Tissues 
The immunohistological reactivity of 6D5 monoclonal antibody was evaluated in formalin 
fixed and paraffin embedded human liver tissue samples (Table 4.2).  
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Table 4.2 Characteristics of human liver tissue samples 
Diagnosis Age ± SD 
Sex 
Male Female 
HCC (n=14) 66,66 ± 12,82 7 5 
Well differentiated (n=2)     
Moderately differentiated (n=10) a     
Poorly differentiated (n=2)    
Cirrhosis (n=46) 52,63 ±16,56 9 15 
Active Cirrhosis (n=26)    
HBV (n=6)    
HCV (n=3)    
Unknown (n=17) b    
Inactive Cirrhosis (n=8)    
HCV (n=2)    
Unknown (n=6)    
Primary Biliary Cirrhosis (n=9)    
Secondary Biliary Cirrhosis (n=3) b    
HBV Carrier (n=10) 31,20 ± 18,94 9 1 
Chronic Active Hepatitis B (n=15) 29,66 ± 06,89 12 3 
Mild (n=5)    
Moderate (n=5)    
Severe (n=5)    
Chronic Active Hepatitis C  (n=15) 66,66 ±12,82 8 7 
Mild (n=5)    
Moderate (n=5)    
Severe (n=5)    
Steatohepatitis (n=11) 42,00 ± 16,76 9 2 
Normal (n=19) 33,87 ± 15,12 16 3 
a : two patient’s sex and age are not found in data 
c : one patient’s age is not found in data 
We examined cytoplasmic staining of hepatocytes in 116 non-tumor cases and found no 
reactivity in 106 samples (92%) (Fig 4.7).  
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Figure 4.7 No immunoreactivity with 6D5 mAb in non-tumoral liver tissues. 
Representative images of normal liver (A), HBV carrier (B), chronic active hepatitis C (C),  
chronic active hepatitis B (D), steatohepatitis (E), secondary biliary cirrhosis (F), primary 
biliary cirrhosis (G) and reactive changes (H)  samples are shown. (Scale bars for all images 
50 µm)  
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The remaining 10 samples (9%), consisting of 2 normal liver, 2 steatohepatitis, 1 HBV 
hepatitis, 1 HCV hepatitis and 4 cirrhosis cases, were stained with the antibody. Of these 
positive samples, only one active cirrhosis case displayed diffuse staining, the remaining 9 
samples being stained focally. Interestingly, stained hepatocytes were located at periportal and 
perivenular areas, suggesting liver tissue reactivity against inflammatory conditions, since 
these zones are well known as sites of hepatocyte regeneration from precursor cells (Yoon, 
Choi et al. 2004). We also observed focal staining of portal capillary endothelial cells and 
portal bile duct epithelial cells in 28 (24%) and 8 (7%) samples, respectively. However, these 
cells were assessed as reactive because of their focal and restricted staining, as well as their 
distinct morphology (Fig. 4.8). The staining of aforementioned cell types in non-HCC cases is 
presented in Table 4.3.  
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Figure 4.8 Focal staining of non-HCC samples with 6D5 mAb. In some non-neoplastic 
liver cells, some capillary endothelial cells (A) at portal tract, periportal/perivenular (B), bile 
duct epithelial cells (C) and lobular hepatocytes (D) showed focal staining (arrows). (Scale 
bars for all images 50 µm) 
 
Table 4.3 Staining of Non-HCC cases with 6D5 monoclonal antibody 
  
Diagnosis 
# Stained Cases 
Hepatocytes
Reactive Endothelial 
Cells 
Reactive Bile Duct 
Epithelial Cells 
Normal Liver (n=19) 2 1 1 
Steatohepatitis (n=11) 2 4 1 
HBV Carriers (n=10) 0 0 0 
HBV Hepatitis (n=15) 1 1 0 
HCV Hepatitis (n=15) 1 3 1 
Cirrhosis (n=46) 4 19 5 
Total (116) 10 (9%) 28 (24%) 8 (7%) 
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4.1.2.5 Diffuse and Strong Staining with 6D5 Monoclonal Antibody in Tumoral 
and Non-Tumoral Areas of HCC Cases 
Next, we continued our immunohistochemical analyses in tumor tissues deriving from 14 
HCC patients. 12 of the cases had also clinically diagnosed for cirrhosis. Two well-
differentiated, 9 moderately differentiated and 3 poorly differentiated tumors were examined 
both in tumoral and adjacent non-tumoral areas, and cytoplasmic staining of cells with 6D5 
antibody was assessed. Tumor cells were stained with 6D5 antibody in all studied HCC 
samples, (100%) (Fig. 4.9). Out of 14 tumor samples, diffuse, moderate and focal positivity 
were observed in 7 (50%), 4 (29%), and 3 (21%) cases, respectively. However, we could not 
establish any correlation between the differentiation state and staining pattern of tissues 
because of the small size of our tumor samples. 12 samples also displayed focal staining of 
endothelial cells (86%), in accordance with tumor neovascularization phenomenon. The high 
occurrence of reactive endothelial cells in HCC was not surprising, as tumor development is a 
culmination of tissue inflammation. However, bile duct epithelial cells were absent in all 
cases due to the loss of the portal tract organization in tumoral zones of HCC samples.  
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Figure 4.9 Tumor cells stained with 6D5 mAb in HCC samples. Diffuse and strong 
staining with 6D5 was observed both in tumoral (A-left) and tumor-adjacent tissue areas (A-
right) of HCC cases. Higher magnification of tumoral cells (B) and adjacent tissue (C) are 
seen in detail. (Scale bar: 250 µm for A and, 50 µm for B and C) 
 
As for the examination of hepatocytes in non-tumoral areas of HCC samples, we evaluated 13 
cases, since 1 moderately differentiated HCC was lacking non-tumor tissue. Unlike the non-
reactivity of hepatocytes in samples deriving from normal liver and benign liver diseases, 
peripheral tissues of HCC cases displayed variable reactivity with 6D5 antibody (10/13; 
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77%). Most of the cases (8/13) were scored as diffusely positive (62%); moderate and focal 
positivity was observed for 1 case each (8%) and 3 cases remained completely negative (23%) 
(Table 4.4).  
 
Table 4.4 Staining scores of HCC cases with 6D5 monoclonal antibody 
C
as
e 
N
o 
D
ia
gn
os
is
 
D
iff
er
en
tia
tio
n 
Staining Score 
Tumor Non-tumoral area 
T
um
or
 
 c
el
ls
 
E
nd
ot
he
lia
l 
ce
lls
 
H
ep
at
oc
yt
es
 
E
nd
ot
he
lia
l 
ce
lls
 
B
ile
 d
uc
t 
ep
ith
el
ia
l 
ce
lls
 
1 
HCC + 
Cirrhosis Moderate F F ND ND ND 
2 
HCC + 
Cirrhosis Moderate F F F F N 
3 
HCC + 
Cirrhosis Moderate M F D F F 
4 
HCC + 
Cirrhosis Poor F F N F N 
5 
HCC + 
Cirrhosis Moderate D F D F N 
6 
HCC + 
Cirrhosis Moderate D F D F F 
7 
HCC + 
Cirrhosis Moderate M N D N N 
8 
HCC + 
Cirrhosis Moderate D F D N N 
9 
HCC + 
Cirrhosis Well D F D F F 
10 
HCC + 
Cirrhosis Well D F N N N 
11 HCC Moderate D F D ND ND 
12 
HCC + 
Cirrhosis Moderate M F D N F 
13 HCC Poor M F N ND ND 
14 
HCC + 
Cirrhosis Poor D N M N N 
Staining scores expessed as D;diffuse, M:moderate, F: focal, N:negative ND: not determined. 
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In tumor periphery, the staining of endothelial cells and bile duct epithelial cells could only be 
evaluated in 11 cases. Endothelial cell reactivity was found in 6 of 11 cases (55%) and was 
significantly lower than that of tumoral area (86% vs. 55%, p<0.05), yet remained higher than 
that of non-HCC cases (55% vs. 24%, p<0.05). However, bile duct epithelial cells were more 
restrictedly stained (4/11; 36%) than endothelial cells, but 4.5 fold more reactive than ductular 
epithelia of normal liver and benign liver disease samples (36% vs. 8%, p<0.05) 
When evaluated along with our non-HCC tissue staining data, these results strongly suggest 
that 6D5 antibody recognized proteins overexpressed in HCC in a specific manner. Diffuse 
and strong immunoreactivity was also observed in non-tumoral liver tissue adjacent to 
tumoral area, suggesting a crosstalk between HCC and tumor microenvironment.  
4.1.2.6 6D5 Reactivity Refers to Liver Tumorigenesis not Cellular Proliferation 
Next, in order to evaluate the usefulness of our antibody as an HCC specific tissue marker, we 
compared 6D5 staining pattern with those of AFP and Ki-67 antibodies in a restricted group 
of patient tissues consisting of 8 cirrhotic and 4 HCC samples. None of the samples reacted 
with AFP antibody, except one secondary biliary cirrhosis tissue, which stained focally. 
Variable Ki-67 reactivity (5% - 20%) was observed for all 4 HCC cases (Fig 4.10) and the 
same secondary biliary cirrhosis sample, which had shown AFP positivity. However, 6D5 
diffusely stained 3 HCC and focally stained 1 HCC cases. On the other hand, our antibody 
reacted in a diffuse manner with one active cirrhosis sample, which failed to be stained with 
neither of the AFP and Ki-67 antibodies (dysplastic nodule). Moreover, the secondary biliary 
cirrhosis tissue that was positive both for AFP and Ki-67 (Fig 4.11), remained negative with 
6D5 staining (Table 4.5). All together, these data implicate that 6D5 ligand is not a non-
specific proliferation marker but rather a protein expressed in early stages of liver 
tumorigenesis.  
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Figure 4.10 Tumor cells and adjacent non tumoral area staining with Ki67 in HCC 
samples. Ki67 positivity is seen in tumor (A-left) and tumor-adjacent tissue (A-right) showed 
no immunoreactivity with Ki67 antibody. Higher magnification of tumoral cells (B) and 
adjacent tissue (C) are seen in detail. (Scale bar; 250 µm for A and 50 µm for B and C) 
 
 
Figure 4.11 Secondary biliary cirrhosis tissue staining with Ki-67 and AFP. Ki67 
positivity is seen in nodular structure of the cirrhotic tissue (A), in contrast AFP staining is 
not seen in the same section (B). (Scale bars; 200 µm) 
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Table 4.5 Comparison of 6D5 staining with Ki-67 and AFP reactivity 
Case No Diagnosis 
Staining 
Tumor Non-tumor 
6D5 Ki-67 AFP 6D5 Ki-67 AFP
1 Macronodular Cirrhosis       N N N 
2 Macronodular Cirrhosis       N N N 
3 Active Cirrhosis       D N N 
4 Active Cirrhosis       N N N 
5 Inactive Cirrhosis       N N N 
6 Active Cirrhosis       F N N 
7 Active Cirrhosis       N N N 
8 Secondary biliary Cirrhosis       N P F 
9 HCC + Cirrhosis D P N D N N 
10 HCC + Cirrhosis D P N D N N 
11 HCC + Cirrhosis F P N N N N 
12 HCC D N N N N N 
Staining scores expessed as D;diffuse, M:moderate, F: focal, N:negative ND: not determined, P: positive 
staining for Ki67. 
 
4.1.2.7 Characterization of 6D5 Monoclonal Antibody Target Proteins  
4.1.2.7.1 Epitope Mapping 
A protein microarray (Imagenes, Germany) containing bacterial clones expressing human 
testis tissues recombinant His-tagged proteins derived from cDNA libraries was screened with 
the 6D5 mAb. The probing with 6D5 antibody revealed four big, four middle, and three small 
size positive spot clones on PVDF membrane (Fig. 4.12). After analyzing spot coordinates, 
six of them were selected because of their high reactivity. Sequencing of these 6 spot clones 
by Imagenes revealed cDNA sequences inserted into pQE plasmids (Fig. 4.13). These cDNAs 
were browsed in BLAST to identify potential peptide sequences and eventually the epitopes 
of the 6D5 mAb. For each clone, conceptually translated proteins from all six reading frames 
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were assessed. The lengths of the translated reading frames were calculated, and all amino 
acid sequences were used to search the combined protein sequence databases for homologous 
sequences, using the BLAST server at the National Center for Biotechnology Information 
(NCBI). The raw sequences of clones were read out of the sequencer by Imagenes. One of 
these sequences is represented in Fig. 4.14. One of them translated a peptide sequence that is 
shown Fig. 4.15. These six sequences were also aligned in CLC workbench software 
(www.clcbio.com) to draw a consensus sequence (Fig. 4.16) and the consensus sequence was 
submitted to NCBI BLAST database. Concensus sequence hit the candidate targets (Table 
4.6). Pair-wise deduced amino acid sequence comparison was done by using Clustal W 
software (Thompson, Higgins et al. 1994). Phylogenetic analysis of our six isolates sequences 
was performed by using CLC workbench software (www.clcbio.com).  
 
Table 4.6 Candidate 6D5 mAb targets identified by analysis of protein microarray 
Acc Name Protein Description Function 
ZFYVE1  Zinc finger FYVE domain-containing protein 1 Membrane trafficking and 
cell signaling  
TJP2 Tight junction protein 2 (zona occludens 2) Encodes a zonula 
occludens-the membrane-
associated guanylate 
kinase 
NT5C1B  Cytosolic 5'-nucleotidase 1B isoform 5 Catalyze production of 
adenosine 
RDH14 Retinol dehydrogenase 14 (all-trans/9-cis/11-
cis) 
Exhibits an 
oxidoreductive catalytic 
activity towards retinoids 
ZXDA  Zinc finger, X-linked, duplicated A Encodes one of two 
duplicated zinc finger 
genes on chromosome 
Xp11 
QRICH1  Glutamine-rich protein 1 Glutamine-rich putative 
transcriptional adaptor 
protein ( TIG-1) 
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Figure 4.12 Western image of peptide microarray displaying the entire cDNA library 
expressed proteins. 6D5 mAb probing of the PVDF membrane resulted positive signals 
(arrows). Coordinates of eleven spots (X,Y) and duplicate pair motifs (p) are seen. A total six 
clones consisting of four big and two middle size spots (14,34 and 17,44) were selected for 
sequencing of cDNAs.  
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Figure 4.13 Six clones of cDNAs revealed by sequencing the positive spots. Positive spot 
coordinates were sent to the company (Imagenes). Target clones were analyzed from the 
microarray bacteria library. Insert clones were sequenced, and shown in six rows.  
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Figure 4.14 Representative 6D5 mAb target clone cDNA sequence with insert 
explanation. The raw sequences of the clone, read out of the sequencer, are seen. Part of the 
vector sequence is indicated as HisTAG in yellow and clone insert in grey color.  
 
 
 
Figure 4.15 Representative in-frame translation of an insert clone. Reading frame analysis 
of cDNA sequences was done for possible expressed peptide sequence. In the translated 
peptide sequence HisTAG is indicated in yellow, first stop is in red color. 
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Figure 4.16 Consensus sequences of cDNAs of targets clones. Parts of six clones of cDNA 
sequences were seen as 181, 010, 811, 413, 614 and 214 (left side). Alignment of these six 
sequences resulted consensus nucleotides (stars). Good consensuses for these sequences were 
indicated with dark red color.  
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4.1.2.7.2 2D Electrophoresis 
As an alternative approach we performed 2D gel electrophoresis of proteins 
immunoprecipitated with 6D5 mAb. We also blotted a replica of these gels and probed it with 
the 6D5 antibody. Proteins detected in 2D gel and western blotting were then compared, and 
matching protein spots were excised for mass spectrometry analysis (Fig 4.18). 
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Figure 4.17 2D-PAGE and western analysis of HUH7 proteins. Immuno-precipitated 
HUH7 total proteins were loaded onto two identical pH 3–10 IPG strips and separated in into 
two 2D-PAGE. One of the gels was stained with SYPRO (A), the other 2D gel (B) was semi-
blotted on the PVDF membrane and then stained with SYPRO. PVDF membrane was probed 
with 6D5 mAb (C). Possibly target spots of 6D5 mAb is shown as H8, B9, D9, E9, G9 and 
H9 in 10% SDS-PAGE-SYPRO stained gel. In this gel two of spots from markers (A10, B10) 
extracted as external control for MALDI-TOF analysis. C8, D8, E8, F8, and G8 spots were 
cut as controls of the 6D5 mAb targets.  
 
4.1.2.7.3 MALDI Analysis  
We extracted and separated the 6D5 immunoreactive protein spots by SDS-PAGE, digested it 
with trypsin, and subjected it to mass spectroscopic analysis to identify amino acid sequence 
by peptide mass fingerprinting. We obtained MS spectras from the tryptic peptides. For 
reliable proteomic identification, we selected high-score peptide sequences with only proteins 
with a confidence score of more than 99%, and BLASTp comparison of de novo sequences 
with the NCBI nr mammalian protein database. Data were also blasted against the sequence 
databank using ProteinLynx Global Server 2 software (Waters/Micromass UK Ltd., 
Manchester, UK). Data also were searched by the tandem mass spectrum database matching 
tool Mascot. Redundant proteins or protein isoforms that could not be differentiated from 
each other on the basis of the MS data were presented as a unique protein group. As a result, 
21 unique proteins were identified. The list of proteins identified in this study together with 
their confidence scores and Entrez gene annotations are shown in Table 4.7.  
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Table 4.7 Proteins identified by mass spectrometry analysis 
Acc 
Num Acc Name Score 
Peptide 
Match 
Count
Covarage MW pI Protein Description 
P79114 MY10_BOVIN 9.2994 17 7.5536 235689 5.9509 Myosin X 
09HD67 MY10 
HUMAN 
8.6434 17 7 .7745 237240 5.7697 Myosin X 
P28858 DPOL HSVE8 7.7612 13 9.8361 135870 6.2324 DNA polymerase 
EC2777 
Q96AA8 Y555 
HUMAN 
7.7503 12 13.0864 94875 5.7876 Hypothetical protein 
KIAA0555 
P70589 MY5B RAT 7.6084 27 12.2969 213586 6.5158 Myosin Vb Myosin 5B 
Myosin heavy chain myr 6
P18709 VTA2 XENLA 7.4475 19 9.1885 201417 9.2697 Vitellogenin A2 precursor 
VTGA2 Contains Lipo 
P08582 TRFM 
HUMAN 
7.3552 12 14.2276 80190 5.5909 Melanotransferrin 
precursor Melanoma 
associated 
014139 HRP3 SCHPO 7.2879 14 3.2939 159279 8.3023 Chromodomain helicase 
hrp3 
O9ULV0 MY58 
HUMAN 
7.1188 20 13.254 146278 8.7874 Myosin Vb Myosin 5B 
Fragment 
090Y53 NPH1 MOUSE 7.0531 8 9.4614 76987 4.966 Mephrocystin 
061116 ZF93 MOUSE 6.5529 11 12.093 72965 8.5214 Zinc finger protein 93 Zfp 
93 
P23116 IF3A MOUSE 6.3745 14 10.2679 161851 6.3393 Eukaryotic translation 
initiation factor 3 subunit 
P39806 SALM DROVI 6.3254 16 11.4836 153648 8.3587 Homeotic protein spalt 
major 
056307 80AL THEMA 6.1873 13 8.5793 127527 5.3948 Beta galactosidase 
EC32123 Lactase 
P14748 REC1  USTMA 6.1778 6 10.3448 56823 6.7592 REC1 protein 
P24384 PR22 YEAST 6.1205 17 11.179 129928 7.6741 Pre mRNA splicing factor 
RNA helicase PRP22 
P28561 APCE AGLNE 6.1144 11 11.6384 101090 9.5894 Phycobilisome linker 
polypeptide Anchor 
polypeptide 
043876 SPS VICFA 6.0933 13 11.5203 118130 5.957 Sucrose phosphate 
synthase EC24114 UDP 
glue 
P90829 DPOD CAEEL 6.0899 16 12.8585 120752 8.4386 DNA polymerase delta 
catalytic subunit EC2777 
P14605 CYAA 
SCHPO 
6.0367 14 7.4468 190213 5.8032 Adenylate cyclase EC 4 6 
1 1 ATP pyrophosphate 
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5 DISCUSSION AND CONCLUSION 
 
Hepatitis B infections in developing countries and HCV epidemics and excessive alcohol 
intake in western populations are the major causes of liver cirrhosis (Fattovich 1998). On the 
other hand, HCC is an end-stage disease which is the major cause of morbidity in cirrhotic 
patients (Bolondi, Sofia et al. 2001). Hence, patients with chronic liver diseases constitute the 
population at high risk, which must be screened routinely for the early detection of HCC. AFP 
has poor sensitivity and specificity for liver cancer and, is far to be a significant detection tool 
except its use with hepatic ultrasonography in combination (Soresi, Magliarisi et al. 2003). 
Other promising, non-invasive serum markers have not entered yet into routine clinical 
practice. Therefore, the need for developing novel HCC markers led us to generate 
monoclonal antibodies. We expected to find out new antibodies with high specificity and 
sensitivity for liver cancer, and assessed in vitro and in vivo reactivity to achieve our goal. 
5.1 Expression Pattern of SIP1 Monoclonal Antibody 
SIP1 has been reportedly shown to mediate EMT and disease aggressiveness in human tumors 
(Comijn et al., 2001; Elloul et al., 2005). Several studies indicated increased levels of SIP1 
transcripts in association with invasion and metastasis in cancers with advanced stages 
(Miyoshi, Kitajima et al. 2004; Imamichi, Konig et al. 2007). However, a comprehensive 
study on SIP1 protein expression in human normal and tumors tissues has not been 
performed. We produced two mAbs using the N-terminal 360 amino acids of human SIP1 
protein as an antigen and assessed their immunoreactivity in cell lines and tissue arrays. Close 
homology between human and mouse SIP1 proteins allowed us to evaluate the specificity of 
novel SIP1 antibodies in overexpression studies. Immunofluorescence analysis of 
A431/WTSIP1 cells with Tet-on doxycyline-inducible wild-type mouse SIP1 expression 
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revealed nuclear localization of SIP1 in only doxycycline-induced cells (Fig 4.1). This result 
also suggests that 1C6 and 6E5 recognize epitopes shared in both human and mouse proteins.  
Endogenous SIP1 expression was analyzed in HCC cell line SK-HEP-1 and colorectal cancer 
cell lines SW480 and SW620. SK-HEP-1 is a well-known invasive HCC cell line (Lin, Ke et 
al. 1998); SW480 and SW620 cell lines were established from the primary and metastatic 
tumors of the same patient, respectively (Leibovitz, Stinson et al. 1976). Consistent with the 
role of SIP1 in inducing EMT phenotype, we found higher SIP1 transcript levels in SW620 
and SK-HEP-1 cells compared to SW480 cell line (Fig 4.4). SIP1 expression analysis in 
western blot and qRT-PCR was almost consistent with a basal expression in SW620 and 
SW480, and an apparent upregulation in SK-HEP-1. Although there was a ~15 fold SIP1 
overexpression in metastatic SW620 cells when compared to SW480, the significance of this 
difference is questionable given the SIP1 expression in SK-HEP-1 in thousands scale. 
Moreover, western blotting revealed protein bands other than the expected 190 kDa size of 
SIP1 protein. In fact, a previous comprehensive analysis through human and mouse tissues 
revealed multiple transcripts of SIP1 in both species (Bassez, Camand et al. 2004). Taken 
together with the immunofluorescence data, these results suggest that SIP1 protein expression 
is tightly regulated, and may also indicate the existence of alternative SIP1 transcripts. 
However, at this point, we cannot exclude the possibility of non-specific signal or protein 
degradation for the aforementioned protein bands with lower molecular weights.  
In contrast to nucleus-restricted expression of SIP1 in A431 SIP1 inducible system, most of 
the analyzed tissues displayed cytoplasmic protein expression. One explanation might be that 
while cell lines are grown in isolation in culture, tissues are subject to signals from their 
neighboring cells that may regulate intracellular SIP1 localization. Additionally, cellular 
stress induced by continuous culture of cell lines may affect the intracellular SIP1 destination. 
Consistent with our immunohistochemistry findings, a recent report also indicated 
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cytoplasmic expression of SIP1 in ovarian tumors (Yoshida, Horiuchi et al. 2009). Strong 
SIP1 expression in normal epithelial cells including hepatocytes, kidney tubules, stomach 
glandular epithelium and colon surface epithelium suggests the co-existence of E-cadherin 
and SIP1. Moreover, SIP1 appears to be prevented from translocation into nucleus in these 
tissues. It is therefore plausible to state that, unlike ZEB1, SIP1 and E-cadherin expression is 
not necessarily mutually exclusive. Among the analyzed tissues, most of the normal tissues 
expressed SIP1 from moderate to strong intensity, and we found SIP1 overexpression only in 
kidney, breast, lung and uterus tumors. On one hand, this differential expression may suggest 
a protective role for SIP1 against tumorigenesis. In fact, SIP1 was shown to directly repress 
cyclin D1 (Mejlvang, Kriajevska et al. 2007). Also, induced expression of SIP1 was reported 
to be partly responsible for hTERT repression in HCC cells (Ozturk, Erdal et al. 2006). On the 
other hand, SIP1 may be implicated in tumor development irrespective of its role in inducing 
EMT. In accordance with our results that SIP1 was up-regulated in some tumors, we recently 
showed that SIP1 protects cancer cells from DNA damage-induced apoptosis (Sayan, 
Griffiths et al. 2009). Also, SIP1 takes part in the TGF-β pathway and the effects of TGF-β on 
cells are variable and depend on many factors including cell type and physiological state of 
tissues (Postigo 2003; Massague 2008).  
Given the functional role of SIP1 as a transcriptional repressor, this and aforementioned 
studies suggest additional levels of regulation on SIP1 activity in tumors in a tissue and/or 
context-dependent manner. Downstream to TGF-β signaling, ZEB1 and SIP1 regulate 
transcription of target genes in conjunction with SMADs and CtBPs. ZEB1 and SIP1 were 
shown to have opposing effects on transcriptional regulation (Postigo 2003) A feedback 
mechanism was described in which ZEB1 and SIP1 show antagonism by differential 
recruitment of co-activators and co-repressors to SMAD complexes, respectively (Postigo, 
Depp et al. 2003). In addition, the expression of ZEB1 and SIP1 was shown to be down-
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regulated by micro RNAs (Gregory, Bert et al. 2008). The effects of these post-transcriptional 
regulation mechanisms on SIP1 protein might be explored by using these novel mAbs in 
further functional studies. 
Herein, we performed a pilot study for the understanding of tissue/tumor specific SIP1 protein 
expression with the newly developed SIP1 specific antibodies using multi-tissue arrays. We 
showed that SIP1 protein levels increased only in a restricted group of tumors and most 
normal tissues displayed SIP1 expression at some extent. We feel to stress a drawback of 
staining multi-tumor arrays that color reaction has to be stopped when a detectable signal 
from majority of the samples is observed. Thus, our staining is optimal for high/medium SIP1 
expressing tissues and may be sub-optimal for low SIP1 expressing ones. Lower SIP1 
expressing tissues may have to be re-tested at their optimal conditions for a better 
understanding of SIP1 function in tumor development. Our recent paper that we analyzed 
SIP1 expression by immunohistochemistry and described SIP1 protein overexpression as a 
marker of poor prognosis in bladder cancers is a good example that SIP1 can be identified as a 
pro-metastatic protein (Sayan, Griffiths et al. 2009).  
To sum up, our observation that SIP1 localized predominantly to the cytoplasm in both tumor 
and normal tissues suggests the implication of unidentified regulatory mechanisms that 
prevent translocation of SIP1 into the nucleus. This, in turn, adds another level of complexity 
to the control of EMT program in tumors progressing towards metastatic state. Therefore, our 
findings bring novel opportunities to further elaborate the role of SIP1 in tumor development. 
5.2 Expression Pattern of 6D5 Monoclonal Antibody 
The fact that our 6D5 antibody recognized several bands in western blot analyses with HCC 
cell lines (Fig 4.5) led us to seek known HCC markers displaying different forms and showing 
the same pattern as 6D5 in similar studies. The most widely used HCC tumor marker is AFP 
77 
 
which may be translated from multiple RNA transcripts (i.e., 2.2, 1.7, 1.6 and 1.35 kb) 
resulting in the generation of protein isoforms with molecular weights similar to those of 6D5 
ligands (Celikkaya, Ciraci et al. 2007). However, previous studies have clearly shown that 
AFP expression is restricted to well differentiated cell lines and absent in others. Therefore, 
according to our western blot experiments, we excluded the possibility that 6D5 antibody is 
directed against AFP epitopes, since 6D5 ligands are expressed in all HCC cell lines 
regardless of their differentiation state.  
Another protein, which is subjected to intensive investigation, is glypican-3, and results from 
many studies support its usefulness as a promising marker for HCC (Kandil, Leiman et al. 
2007). This protein too, when expressed, gives rise to several isoforms, whose molecular 
weights approximate to those of protein bands we observed in our western blot analyses. 
However, in one study, glypican-3 expression has been shown to be absent in SK-Hep1 cell 
line (Jiang, Man et al. 2006).The strong reactivity of our antibody with cell lysate of SK-Hep1 
cells allowed us to exclude this HCC marker as the ligand of 6D5. This conclusion is further 
supported by studies, which have shown cell surface expression and secretion of glypican-3 
from hepatocytes (Grozdanov, Yovchev et al. 2006); however, the staining of human liver 
tumor samples with 6D5 was strictly cytoplasmic. 
In all stained non-HCC cases, the ratio of stained cells to total tissue cell population did not 
exceed 1%. This was well below our criteria of focal staining, yet we represented this 
reactivity pattern since the affected cell types (reactive bile duct epithelial cells, periportal 
hepatocytes, etc.) constitute the origins of precursor cells involved in hepatocyte regeneration 
in response to liver damage and/or inflammation (Matthews and Yeoh 2005). Moreover, 
among the stained 45 cases, only 9 displayed moderate staining intensity, the others being 
stained weakly. 
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The most striking feature of our immunohistochemistry data in non-HCC cases was the non-
reactivity of lobular hepatocytes with 6D5 antibody (Fig 4.7). Therefore, we hypothesized that 
the staining in other regions of the organ is due to the regenerative capacity of the liver 
reactive to cellular inflammation and/or damage. The periportal and perivenular staining  (Fig 
4.8) dominating in HCV hepatitis and steatohepatitis, respectively further supports this idea, 
since these zones are well known as the primarily affected area of cellular damage in 
abovementioned liver pathologies (Matthews and Yeoh 2005). Periportal staining in cirrhosis 
cases was accumulated in the samples deriving from primary and secondary biliary cirrhosis 
cases. In this group, 6D5 antibody stained periportal hepatocytes in 7 of the 12 samples. Here, 
our results were consistent with the fact that cellular damage, which is due to auto-antibodies 
and choleostasis in primary and secondary biliary cirrhosis, respectively, initiates at portal 
tract. Another interesting finding emerging from our immunohistochemistry analyses was the 
restricted staining of portal capillaries of endothelial cells (30 of 116 cases) and to a much 
lesser extent that of bile duct epithelial cells (9 of 116 cases only). We also evaluated both 
staining as reactive to cellular inflammation and/or damage, since in the majority of samples 
these two zones were not stained at all.  
Unlike the non-reactivity of lobular hepatocytes in non-tumoral samples, the staining of tumor 
cells in all examined cases strongly implicates the specificity of 6D5 mAb for HCC (Fig 4.9). 
But, more interestingly, lobular and/or cirrhotic hepatocytes at tumor periphery were stained 
in the majority of cases, and even with a greater intensity than tumoral cells. This observation 
is especially striking in that no hepatocyte reactivity was seen in non-tumoral tissues, 
including our 24 cases of cirrhosis. One possible explanation of this phenomenon might be 
that hepatocytes in the nodules at tumor periphery were indeed other than cirrhotic cells and 
most probably dysplastic cells, since none of the cirrhosis cases had displayed reactivity with 
our antibody. Thus, we suggest that 6D5 target proteins expression occurs at early stages of 
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tumor development where cirrhotic cells are getting transformed. The staining of reactive 
endothelial cells and bile duct epithelial cells at tumor periphery was also stronger than that of 
the same cells in non-tumoral samples (43% vs. 21% and 29% vs. 5%, respectively). We then 
hypothesized that tumor development, as being a culminating inflammatory event and a 
damaging process for normal parenchyma, caused this higher reactivity of aforementioned 
cells with 6D5 antibody.  
In conclusion, these results clearly demonstrated that 6D5 monoclonal antibody specifically 
reacts with liver tumor cells and/or the protein that the antibody recognizes is overexpressed 
at early stages of liver tumor development.  
In our study with 6D5 monoclonal antibody, we have proven that the protein recognized by 
this reagent showed great specificity and sensitivity for HCC for several reasons. First, the 
antibody recognized all HCC cases of our study group and did not react with organized 
lobular hepatocytes in other liver lesions. Second cirrhotic hepatocytes were stained only in 
tissues deriving from HCC, but not in other cirrhosis cases. Third, besides the staining of 
endothelial cells lining tumor capillaries, 6D5 also reacted with endothelial cells of liver 
tissue vasculature in non-tumoral area. But, this observation again, was restricted to HCC 
cases only. And finally, the staining of bile duct epithelial cells was observed in tumor tissue 
sections and, such staining pattern was not encountered in other histopathological groups.  
5.3 Identification of 6D5 Monoclonal Antibody Targets by Proteomics 
Peptide microarrays are increasingly being used to define antibody epitopes. Probing of the 
6D5 antibody with protein microarray revealed positive spot clones. Six of them were 
selected because of their size (Fig 4.12). Sequencing of these 6 spot clones by Imagenes 
revealed their cDNA sequences (Fig 4.13). Devoted to the polypeptide blast database search, 
the possible translates of these cDNA sequences did not give the absolute candidate epitopes-
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targets for HCC because of low percentage in protein matches. Additionally consensus 
sequences of our clone’s cDNA cannot indicate or hit any real or putative protein target over 
99% coverage. The problem can be explained in some way. Antibodies may recognize a 
linear stretch of amino acids on three dimentional (conformational) structure that is not real 
sequence of the protein. So this binding might mimic the real binding on peptide sequences. 
The size of antibody binding site, a continuous epitope, was found to be usually between 5 
and 8 amino acids in length. Consequently, the amino acids of the peptides attracting antibody 
binding site might result with false positivity. This can also be the result of either an 
accessibility of the key amino acids within the longer sequences or due to the preformation of 
secondary structures necessary for the antibody binding rather than the length of the epitope 
itself.  
Using 2D PAGE analysis, in this study, 4 spots from the gel were found 6D5 immunoreactive 
that is confirmed by western analysis. Protein sequencing of 6D5 targets by mass 
spectrometry showed that the proteins have unusual tandem, non-perfect coverage for the 
estimation peptide sequence. There are many issues associated with the non-perfect coverage 
of components of a complex peptide analyte solution containing mixture of proteins. Firstly, 
all peptides do not ionize with the equal efficiencies that are often mixture dependent with the 
same peptide ionizing differently depending on the other components of the analyte mixture 
(Zheng, Ojha et al. 2003). As mass spectrometry continues to improve and as its sensitivity 
increases, the detection of multiple proteins in individual 2D gel spots is likely to pose less of 
a problem in the future. Part of this problem can be overcome by increasing the separation of 
protein spots through the use of multiple narrow range isoelectric focusing strips. Although 
this is certain to reduce the number of proteins migrating to a particular point on a gel, it also 
increases the number of 2D gels that need to be produced for coverage of the entire proteome. 
Using the methodology (Yang, Li et al. 1998), it was possible to assess the validity of using 
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MALDI-TOF intensity coverage values as a crude measure of protein abundance. This 
involved the analysis of the remaining analyte samples containing peptides from the fly lines 
that exhibited an increase in abundance of protein samples.  
Secondly, proteomics sequence databases are subject to time instability and changes over time 
(Batista, del Pozo et al. 2004). Once a sequence has been recorded in a database, it can 
undergo alterations as well. Certain sequences can be subjected to removal from the database, 
invalidating the accession number without providing a replacement. This effect is most 
pronounced for purely theoretical predictions. Change in the prediction algorithm may render 
a number of previous predictions obsolete and suffers the same fluctuations as its source 
databases. 
The other important problem for data analysis in proteomics is standardization. The use of 
specialized protocols and very different data processing pipelines add to this problem. In fact, 
having every single protocol and data processing step documented does not necessarily result 
in allowing reproduction of the analyses performed in order to validate the results, as specific 
steps may not be available to other researchers. The Human Proteome Organization (HUPO) 
(Hanash 2002) has created the Proteomics Standards Initiative (PSI) (Orchard, Hermjakob et 
al. 2005) to tackle both standardization problems. The heterogeneity of standards will need to 
be resolved in full before real progress can be made in this matter. This approach has been in 
place for years for nucleic acid and protein sequence databases and has repeatedly proven to 
greatly aid researchers worldwide.  
In conclusion, in this study, human tissues were used in immunohistochemistry screening of 
6D5 target proteins of and SIP1 by using homemade mAbs. It is found that the high-level 
expression of 6D5 was found to more frequently in human HCCs as compared to normal liver 
and benign liver lesions. In addition, high-level expression of SIP1 was evaluated to be 
significantly associated with normal liver tissues. We found that the expression of SIP1 was 
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semi-quantitatively decreased from normal liver to HCC metastatic carcinoma and the 
expression of SIP1 in normal tissues was significantly higher than that of corresponding 
tumor tissues.  All these results demonstrated that our data could provide a novel approach in 
cancer research and after identifying 6D5 target proteins there will be a translation from basic 
research to clinical applications in the future. 
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6 FUTURE PERSPECTIVES 
 
It is suggested that hepatitis B-related HCC will decrease with vaccination, while hepatitis C-
related HCC will become an increasing problem. Antiviral treatment and chemo-preventive 
agents will prevent HCC development. Whole-population screening will not be an option, but 
screening is justified for individuals who can pay for it. There will be more emphasis on the 
use of tumor markers. The diagnosis of HCC is established serologically (using tumor 
markers), radiologically, cytologically or histologically, either alone or in combination.  
In the protein microarray results, the proteins expressed and purified from the corresponding 
clones detected in a screening experiment can be used for the further validation and 
specification of the discovered interactions. For example after the identification of the targets 
from a novel antibody, the specificity and sensitivity of the interactions can be confirmed by 
Western immunoblotting and transfectant studies. If the proteins were expressed and purified 
in a large scale format, specific protein microarrays can be produced. These protein 
microarrays might be used in routine clinical practice until relevant validation studies have 
been done in many centers. Ultimately, prediction of the most promising biomarkers requires 
prospective validation in carefully designed randomized clinical trials using standardized 
protocols. This will require cooperation across borders and specialties. 
Furthermore, we still do not know whether the molecular profile of a tumor changes at the 
time of disease or even after therapy towards for a more advanced disease. There is little 
information as to whether primary and metastatic tumors always share the same molecular 
profile, although there is some evidence for molecular discordance between early and 
metastatic disease. Therefore our mAbs might be tested in different state of the diseases.  
In the field of proteomics, there is a great interest to find binding reagents that specifically 
interact with the individual protein species. It is recognized that different types of binding 
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molecules or binders selected from libraries generated by combinatorial design of various 
alternative scaffolds, are used to obtain target-specific affinity reagents. For any of these 
binding molecules, there must be a source of target molecules in order to succeed with the 
generation of target-specific binders. For the herein presented study, we may improve 
strategies to recovery of the fragments of the target proteins are successfully produced in 
HCC. Such protein fragments might be then employed to obtain highly target specific 
(monospecific) antibodies after immunization and careful affinity purification strategies. 
Monospecific antibody preparations might be obtained to stain TMA in order to localize the 
target proteins in normal and pathological tissue sections. It is likely that functional 
proteomics, in the sense of looking for differences in protein abundance in various biological 
samples, is a useful strategy to find novel drug candidates for diseases. For example, in a 
publication (Ek, Andreasson et al. 2006), the researchers were guided by information about 
protein localization, obtained from TMA staining, to point out a number of possible drug 
targets for an aggressive cancer form.  
On the other hand, our candidates are open to test with the molecular techniques such as 
siRNA or knockdown or knockout of the targets to improve the validity of the proteomics 
results. 
Finally, technical issues are also important in proteomics approaches with mAbs. At present, 
very few routine clinical laboratories have access to sophisticated molecular techniques, such 
as qRT-PCR, mutational analysis, FISH, and microarray, although most can do 
immunohistochemistry. However, standardized, optimized protocols and antibodies need to 
be applied in order to validate prospective validation; these technologies will also need 
optimization and standardization before being generally accepted as a valid decision-making 
tool.  
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Monoclonal antibodiesSmad-interacting protein 1 (SIP1, also known as ZEB2) represses the transcription of E-cadherin and
mediates epithelial–mesenchymal transition in development and tumor metastasis. Due to the lack of
human SIP1-speciﬁc antibodies, its expression in human tumor tissues has not been studied in detail by
immunohistochemistry. Hence, we generated two anti-SIP1 monoclonal antibodies, clones 1C6 and 6E5, with
IgG1 and IgG2a isotypes, respectively. The speciﬁcity of these antibodies was shown by Western blotting
studies using siRNA mediated downregulation of SIP1 and ZEB1 in a human osteosarcoma cell line. In the
same context, we also compared them with 5 commercially available SIP1 antibodies. Antibody speciﬁcity
was further veriﬁed in an inducible cell line system by immunoﬂuorescence. By using both antibodies, we
evaluated the tissue expression of SIP1 in parafﬁn-embedded tissue microarrays consisting of 22 normal and
101 tumoral tissues of kidney, colon, stomach, lung, esophagus, uterus, rectum, breast and liver.
Interestingly, SIP1 predominantly displayed a cytoplasmic expression, while the nuclear localization of
SIP1 was observed in only 6 cases. Strong expression of SIP1 was found in distal tubules of kidney, glandular
epithelial cells of stomach and hepatocytes, implicating a co-expression of SIP1 and E-cadherin. Squamous
epithelium of the esophagus and surface epithelium of colon and rectum were stained with moderate to
weak intensity. Normal uterus, breast and lung tissues remained completely negative. By comparison with
their normal tissues, we observed SIP1 overexpression in cancers of the kidney, breast, lung and uterus.
However, SIP1 expression was found to be downregulated in tumors from colon, rectum, esophagus, liver
and stomach tissues. Finally we did nuclear/cytoplasmic fractionation in 3 carcinoma cell lines and detected
SIP1 in both fractions, nucleus being the dominant one. To our best knowledge, this is the ﬁrst
comprehensive immunohistochemical study of the expression of SIP1 in a series of human cancers. Our
ﬁnding that SIP1 is not exclusively localized to nucleus suggests that the subcellular localization of SIP1 is
regulated in normal and tumor tissues. These novel monoclonal antibodies may help elucidate the role of
SIP1 in tumor development.y of Science, Department of
A, Turkey.
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Smad-interacting protein 1 (SIP1, also known as ZEB2) encoded by
ZFHX1B is a member of ZEB family of transcription factors. The protein
contains a central homeodomain, CtBP-binding and Smad-interacting
domains and two zinc ﬁnger clusters each at either end (Remacle et al.,
1999; Verschueren et al., 1999). SIP1 directly binds to bipartite E-boxes
on the promoters of different targets bymeans of its zincﬁnger domains
andmediates transcriptional repression (Verschueren et al., 1999). One
of these targets is CDH1, the gene encoding for the epithelial adherensjunction protein E-cadherin, whose transcriptional downregulation
induces epithelial-to-mesenchymal transition (EMT) in developmental
processes and during tumor cell invasion and metastasis (Comijn et al.,
2001). Transcriptional repression ismediated through the association of
SIP1 with the corepressor CtBP, however this interaction is dispensable
at least for the attenuation of CDH1 transcription (Postigo et al., 2003;
van Grunsven et al., 2003). Overexpression of SIP1 in epithelial cells has
also been shown to downregulate constituents of cell–cell junctions
other than E-cadherin (Vandewalle et al., 2005). Although binding of
SIP1 to p300 or pCAF was proposed as a mechanism for transactivation
and other transcriptional activators associated to SIP1 are yet to be
determined, SIP1-mediated upregulation of EMT and invasion related
genes, such as vimentin and matrix metalloproteases, have been
reported (Bindels et al., 2006; Miyoshi et al., 2004; Postigo et al., 2003).
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phenotype, its role in tumorigenesis was ill-deﬁned. In fact, SIP1 was
originally identiﬁed as a binding partner of R-Smads, and shown to be
part of the TGF-β pathway, which is frequently involved in carcinogen-
esis (Verschueren et al., 1999). hTERT repression in breast cancer cells
was partly mediated by SIP1 in a TGF-β dependent manner (Lin and
Elledge, 2003). Also, analysis of senescence arrest of clonal hepatocel-
lular carcinoma cells revealed SIP1 as a mediator of hTERT repression
(Ozturk et al., 2006). Impaired G1/S progression was observed upon
repression of cyclin D1 by SIP1 (Mejlvang et al., 2007). SIP1 was also
shown to contribute to tumorigenesis in a transgenic mouse model of
lymphoma by retroviral tagging (Mikkers et al., 2002). The differential
expression of SIP1 has been described, mostly by RT-PCR, in several
human tumors due to the lack of human SIP1-speciﬁc antibodies. E-
cadherin downregulationwas associated to increased SIP1 expression in
intestinal type gastric carcinoma but not in diffuse type gastric
carcinoma (Rosivatz et al., 2002). Elevated SIP1 expression correlated
inversely with E-cadherin in advanced stages of pancreatic tumors
(Imamichi et al., 2007). Surprisingly, SIP1 and E-cadherin expression
were positively correlated in malignant mesothelioma (Sivertsen et al.,
2006). In the esophagus, differential expression of SIP1 was observed
duringkeratinocyte differentiation.Only stemcell containingbasal cells,
but not parabasal cells and keratinocytes expressed SIP1. Consistent
with this, SIP1 transcripts were present in all studied esophagealFig. 1. Endogenous and induced expression of SIP1 is detected by monoclonal antibodies 1C6
(ZEB1-si) siRNAs. Proteins were extracted 48 h after transfection and western blot was perfo
antibodies. Both SIP1 antibodies did not recognize ZEB1 and can detect endogenous SIP1 ef
compare the new SIP1 MAbs with 5 different commercial antibodies. The results from polycl
are presented in left and right panels, respectively. With the exception of 474, all other comm
in 2 μg doxycycline for 24 h and stained with 6E5 MAb displayed nuclear SIP1 expression (ﬁ
(second row).carcinoma cases (Isohata et al., 2009). High SIP1/E-cadherin ratio
correlated with metastatic disease and poor patient survival in breast
and ovarian carcinomas (Elloul et al., 2005). Elevated SIP1 transcripts
were observed in von Hippel–Lindau-null renal cell carcinomas in a
hypoxia-inducible factor 1 alpha (HIF1α)-dependent manner (Krish-
namachary et al., 2006). Immunohistochemical analysis of ovarian
tumors revealed a stepwise increase of SIP1 frombenign to borderline to
malignant tumors (Yoshida et al., 2009). In oral squamous cell
carcinoma, SIP1 was immunohistochemically detected in a relatively
low proportion of tumors and its expression correlated with poor
prognosis (Maeda et al., 2005). In a previous study, we have found that
SIP1was overexpressed in a series of bladder cancers. Its expressionwas
found to be an independent prognostic factor in bladder cancers and
positively stained cases correlated with poor therapeutical outcome
(Sayan et al., 2009).With the exception of a few and as described above,
most of the expression studies of SIP1 were done using RT-PCR
technique, but SIP1protein levels have been shown to be tightly
regulated by post-transcriptional mechanisms. For instance, Pc2-
mediated sumoylation of SIP1 affects the transcriptional regulation of
E-cadherin (Long et al., 2005). SIP1 has been identiﬁed as a direct target
of miR-200 family andmiR-205 (Gregory et al., 2008; Park et al., 2008).
In this study, we generated 2 new monoclonal antibodies (MAb)
against the N-terminus of SIP1 protein and validated their speciﬁcity
by speciﬁcally downregulating SIP1 protein, and the other ZFHX1and 6E5. (A) HOS2 cells were transfected with control (Neg-si), SIP1 (SIP1-si) and ZEB1
rmed with the indicated antibodies. SIP1 speciﬁc band was detected with 1C6 and CUK
ﬁciently. (B) Control siRNA and SIP1 siRNA transfected HOS2 cell lysates were used to
onal antibodies (goat or rabbit anti-SIP1) and monoclonal antibodies (mouse anti-SIP1)
ercial antibodies were either weak or non-speciﬁc. (C) A431/WTSIP1 cells maintained
rst row), whereas no staining was observed in uninduced cells with the same antibody
Table 1
Immunohistochemistry results of SIP1 expression in human tissues.
Tissue (n=123) SIP1 expression
Cytoplasm Nucleus SIP1-positive structure
Kidney
Tumor (n=18) +++ (17) − Tumoral cells
Normal (n=4) ++ (4) − Proximal–distal tubules
Lung
Tumor (n=14) + (10) − Tumoral cells
Normal (n=3) − (0) − Surfactant ++(3)
Breast
Tumor (n=9) + (5) − Tumoral cells
Normal (n=2) − (0) − −
Uterus
Tumor (n=12) + (5) − Tumoral cells
Normal (n=3) − (0) − −
Liver
Tumor (n=9) ++ (9) − Tumoral cells
Normal (n=2) +++ (2) − Hepatocytes
Stomach
Tumor (n=9) + (4) − Tumoral cells
Normal (n=1) +++ (1) − Glandular cells
Colon
Tumor (n=12) + (4) − Tumoral cells
Normal (n=4) ++ (4) + (4) Surface epithelium
Rectum
Tumor (n=9) + (7) ++ (1) Tumoral cells
Normal (n=1) ++ (1) ++ (1) Surface epithelium
Esophagus
Tumor (n=9) + (5) − Tumoral cells
Normal (n=2) ++ (2) − Squamous epithelium
Mean staining intensities expressed as (−): negative, +: weak, ++: moderate, +++:
strong. Numbers in parentheses represent positively stained cases.
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using these antibodies we explored the expression pattern of SIP1 in
human tumor cell lines and in a variety of tissues. We detected
predominantly cytoplasmic but also nuclear SIP1 staining. Finally,
subcellular fractionation of cell lines showed that SIP1 protein can be
present in the cytoplasm and nucleus of multiple carcinoma cell lines.
To our knowledge, this study is the ﬁrst description of SIP1 protein
expression in a multiple tumor tissue arrays.
Materials and methods
Cell lines, tissues and siRNA transfections
Wild-type mouse SIP1 expressing squamous epidermoid carcino-
ma cell line A431/WTSIP1 with Tet-on doxycycline-inducible SIP1
expression was previously described (Mejlvang et al., 2007).
Osteosarcoma cell line HOS2, hepatocellular carcinoma cell line SK-
HEP-1 and colorectal carcinoma cell lines SW480 and SW620 were
maintained in DMEM supplemented with 10% fetal bovine serum,
100 IU penicillin, 100 μg streptomycin and nonessential amino acids.
Multiple Tumor Tissue arrays were purchased from BioChain Institute,
Inc. (Hayward, CA). siRNAs targeting ZEB1 (Sayan et al., 2009) and
SIP1 (S102364277, Qiagen, Hilden, Germany) were transfected using
Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA). Cells were
collected 48 h after transfection and processed for Western blotting.
Recombinant SIP1 production
The ﬁrst 360 amino acid part coding region of SIP1 (ZEB2) cDNA was
cloned into pET101/D (Invitrogen, Carlsbad, CA) vector with an N-
terminal 6-histidine tag. Recombinant protein was expressed in
Escherichia coli (BL21) and puriﬁed under denaturing conditions using
Ni–NTA resin (Qiagen, Hilden, Germany). Puriﬁed protein then was
refolded and buffer exchanged to phosphate buffered saline (PBS) using
NAP buffer exchange columns (Amersham, Piscataway, NJ). Finally, pure
and folded recombinant protein was concentrated (0.5–1 mg/ml) using
Centripreps (Millipore, Billerica, MA).
Production of monoclonal antibodies
Recombinant SIP1 protein was injected into the peritoneal cavity of
8- to 10-week-old BALB/c mice at 3 week intervals. During the
immunization period, antibody titer of mice sera was evaluated by
indirect ELISA. Brieﬂy, ELISA plates were coated by 100 ng of
recombinant SIP1 protein in carbonate buffer (pH: 9.6). Serially diluted
mice sera were assessed for their immunoreactivity with SIP1 protein.
Alkaline phosphatase conjugated goat anti-mouse IgG (Sigma-Aldrich,
St. Louis, MO) was used as secondary antibody. Colorimetric reaction
generated upon addition of the substrate para-nitrophenyl-phosphate
(Sigma-Aldrich, St. Louis, MO) was measured at A405 in an automated
plate reader (Biotek Instruments, Winooski, UT). Three days after the
ﬁnal boost, fusion of mouse splenocytes and SP2/0 myeloma cells was
performed as previously described (Celikkaya et al., 2007). Hybridoma
supernatants were screened by aforementioned indirect ELISA, and
hybridomas secreting anti-SIP1 antibodies were subjected to single cell
subcloning. Antibody isotype was determined by ImmunoPure Mono-
clonal Antibody Isotyping Kit (Pierce, Rockford, IL) according to
manufacturer's instructions.
Western blotting
Total cell lysates from HOS2, SK-HEP-1, SW480 and SW620 cell
lines were prepared in NP-40 lysis buffer [50 mM Tris–HCl pH 8.0,
150 mM NaCl, 1% Non-idet P40 (v/v) and a cocktail of EDTA-free
protease inhibitors (Roche Diagnostics, Mannheim, Germany)] or by
direct lysis in 2X Laemmli buffer. Nuclear and cytosolic proteinfractions were prepared by NE-PER® Nuclear and Cytoplasmic
Extraction Reagents (Pierce, Rockford, IL) according to manufacturer's
instructions. Protein content was measured by Bradford or BCA assay.
Equalized lysates were run on 8% SDS-PAGE and then transferred onto
polyvinylidene ﬂuoride (PVDF) membranes by using semi-dry
transfer apparatus (Bio-Rad, Hercules, CA). 1C6 and 6E5 hybridoma
supernatants were used as primary antibody. Other antibodies used in
this study are from Bethyl Labs [473 (A302-473A) and 474 (A302-
474A), 1:500; Montgomery, TX], Santa Cruz [SC1 (sc-48789) and SC2
(sc-18392), 1:500; Santa Cruz, CA] and Sigma (WH0009839M1,
1:500; Sigma-Aldrich, St. Louis, MO) for SIP1 immunodetection and
Santa Cruz (sc-25388,) for ZEB1 immunodetection. Rabbit polyclonal
SIP1 antibody (CUK2) was previously described (Sayan et al., 2009).
Horseradish peroxidase (HRP)-conjugated anti-mouse, anti-rabbit
IgG or anti-goat (Sigma-Aldrich, St. Louis, MO) were used as
secondary antibodies at 1:5000 dilution. Protein bands were visual-
ized using Super Signal West Dura or Femto chemiluminescent
substrate (Pierce, Rockford, IL).
Quantitative real-time PCR
SIP1 mRNA expression in colon cancer cell lines SW620, SW480
and hepatocellular carcinoma cell line SK-HEP-1 was determined by
quantitative real-time PCR as described previously (Avci et al.,
2008). The expression of SIP1 in cell lines was measured using
ΔΔCt method and normalized to GAPDH gene. The threshold cycle
of SIP1 cDNA in SW480 cell line, which showed the lowest
expression was set to 1 and relative expression values were plotted
as fold changes.
Immunoﬂuorescence
A431/WTSIP1 cells were grown on cover slips in 6 well plates and
inducedwith doxycycline (2 μg/ml) for 24 h. PBSwas used in allwashing
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in PBS containing 0.3% triton X-100. After blockingwith 2% Bovine Serum
Albumin (BSA) in PBS, cells were incubated for 2 h at room temperature
with hybridoma supernatants. Alexa ﬂuor 488-conjugated anti-mouse
IgG (Invitrogen, Carlsbad, CA) was used as secondary antibody at 1:200
dilution. Nuclei counterstaining was performed with 4′,6-diamidino-2-
phenylindole (DAPI); cover slips were mounted on glass slides and
examined under ﬂuorescent microscope (Zeiss GmbH, Germany).
Merged images were produced by using AxioVision image processing
software (Zeiss GmbH, Germany).Fig. 2. Increased expression of SIP1 in kidney, lung, breast and uterus tumors. Representa
tissues as detected by immunohistochemistry performed by both antibodies. (A) Distal
(D) adenocarcinoma of the uterus, (E) normal lungwith non speciﬁc surfactant staining, (F
(−): negative, +: weak, ++: moderate, +++: strong staining intensity (scale bars: 50 µImmunohistochemistry
A total of 123 tissues spotted on three tissue arrayswere stained twice
by both 1C6 and 6E5 MAbs. Tissue arrays included sections from kidney
(22: tumor18,normal4), lung (17: tumor14,normal3), colon (16: tumor
12, normal 4), uterus (15: tumor 12, normal 3), esophagus (11: tumor 9,
normal 2), liver (11: tumor 9, normal 2), breast (11: tumor 9, normal 2),
rectum (10: tumor 9, normal 1) and stomach (10: tumor 9, normal 1)
tissues. Tissue array slides were deparafﬁnized ﬁrst at 70 °C and then in
xylene. After rehydration in graded alcohol series, glass slides weretive photographs show increased SIP1 expression in tumors relative to their normal
tubule staining in normal kidney, (B) clear cell renal carcinoma, (C) normal uterus,
) squamous cell carcinoma of the lung, (G) normal breast, (H) breast ductal carcinoma.
m).
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oven for 20 min for antigen retrieval. Endogenous peroxidase was
blocked by incubation of slides in 3% H2O2 for 30 min. PBS was used in
all washing steps. Tissue sections were incubated with hybridoma
supernatants for 2 h, and after washing, universal staining kit (LabVision,
Fremont, CA) was used according to manufacturer's recommendations.
3,3′-diaminobenzidine (DAB)wasusedas chromogenand the slideswere
counterstained using Mayer's hematoxylin. Stainings were performed in
triplicate for both antibodies. The sections were evaluated by light
microscopic examination and the intensity of immunostaining in each
section was assessed independently by two observers (E.O and A.O). The
intensity of total SIP1 staining on each sample was scored as previously
described with a slight modiﬁcation (Chen et al., 2006). Brieﬂy the
staining intensitywasgraded relativelybasedon the following scales: 0, 1,
2, and3 fornegative,weak,moderate and strong staining, respectively. An
averaged scorewas reachedas theﬁnal score for each tissuewithmultiple
samples. According to the ﬁnal immunostaining scores, the tissues were
classiﬁed into four groups: negative group (score 0–0.40), weak staining
group (score 0.5–1.4), moderate staining, group (scores 1.5–2.4), and
strong staining group (scores 2.5–3). (−), (+), (++) and (+++)
designationswere used for these four groups, respectively. The staining in
nuclei and cytoplasm was determined separately on each specimen.Results
Monoclonal antibodies 1C6 and 6E5 detect both endogenous and
overexpressed SIP1
Two MAbs, clones 1C6 and 6E5 were obtained by immunizing
BALB/c mice with a partial human SIP1 recombinant protein (aa 1-
360). The isotypes of antibodies were IgG2a and IgG1, respectively
(data not shown). ZEB1 and SIP1 (ZEB2) are members of the zinc
ﬁnger Homeobox 1 gene family. Among these 2 proteins, there is
more than 45% overall protein homology which is much higher (up to
93% identity at C-terminal zinc ﬁnger cluster) in the functional
domains (Vandewalle et al., 2009). Thus, as a ﬁrst step, we wanted to
assess the speciﬁcity of the new antibodies by speciﬁcally knocking
down ZEB1 and SIP1 proteins in HOS2 osteosarcoma cells. As shown in
Fig. 1A, endogenous SIP1 was speciﬁcally downregulated by SIP1
siRNA but not by ZEB1 siRNA and detected by 1C6 MAb. The
authenticity of 1C6 immunoreactive band (190 kDa) is also conﬁrmed
by another SIP1 antibody (CUK2). None of the SIP1 antibodies
detected ZEB1 and ZEB1 antibody did not detect SIP1 (Fig. 1A). As a
second step, we wanted to test the speciﬁcity and strength of several
other commercial SIP1 antibodies. We used control siRNA and SIP1
siRNA transfected HOS2 cell lysates to detect endogenous SIP1. With
the exception of 474, which recognized endogenous SIP1 weakly,
commercial polyclonal SIP antibodies were either very weak (SC1,
SC2) or non-speciﬁc (473) (Fig. 1B, left panel). Also, when compared
with another MAb (Sigma), only 1C6 and 6E5, but not the com-
mercial one recognized SIP1 speciﬁcally (Fig. 1B, right panel). The
speciﬁcity of these new SIP1 MAbs were also validated in the
inducible cell line system A431 containing mouse WTSIP1. By using
both antibodies in immunoﬂuorescence assay, we detected nuclear
expression of SIP1 in these cells maintained in the presence of
doxycycline for 24 h (Fig. 1C). These results showed that the new SIP1
MAbs are speciﬁc and able to detect SIP1 in endogenous levels and
when overexpressed.Fig. 3. Reduced expression of SIP1 in liver, stomach, colon, rectum and esophagus tumo
antibodies and show decreased SIP1 expression in tumors with respect to their normal tissue
the adjacent cirrhotic tissue, (C) normal stomach gland cells, (D) adenocarcinoma of the stom
rectum surface epithelium, (H) adenocarcinoma of the rectum, (I) normal esophagus squamo
+++: strong staining intensity (scale bars: 50 µm).Tissue expression of SIP1 is predominantly cytoplasmic
Next, the tissue expression pattern of SIP1 proteinwas analyzed by
staining formalin-ﬁxed and parafﬁn-embedded tissue arrays with
MAbs 1C6 and 6E5. 22 normal and 101 tumor tissues were examined
by immunohistochemistry and all samples displayed similar reactivity
upon staining by both clones. The SIP1 immunostaining pattern of
tissues was summarized in Table 1. No immunoreactivity was
observed in tissue arrays stained with mouse IgG1 and IgG2a isotype
control antibodies (data not shown).
The majority of tissues displayed cytoplasmic staining of SIP1 and
nuclear expression of SIP1 was observed only in 6 cases consisting of
one normal and one tumor tissues of rectum and four normal colon
samples (Table 1).
Differential expression of SIP1 in human tumors
SIP1 is overexpressed in tumors of the kidney, lung, breast and uterus
1C6 and 6E5 antibodies stained both proximal and distal tubules of
kidney, yet the reactivity of the latter was more intense. Compared to
the tubular epithelium-restricted expression of SIP1 in normal kidney,
SIP1 was extensively expressed in kidney tumors. Out of 18 tumors,
17 clear cell carcinomas displayed strong cytoplasmic staining with
both antibodies (Fig. 2A–B), and one transitional cell carcinoma case
remained negative. Relative to their normal tissues, which failed to
display SIP1 expression, 71% of lung, 56% of breast and 42% of uterus
tumors showed cytoplasmic SIP1 positivity, yet with a weak intensity
(Fig. 2C–H).
Cytoplasmic SIP1 is downregulated in most of the human tumors
The cytoplasm of all 9 hepatocellular carcinoma cases displayed a
moderate intensity of SIP1 expression, which could not reach
however the strong staining pattern of SIP1 in normal hepatocytes
and tumor-adjacent cirrhotic tissues (Fig. 3A, B). Eight of nine
stomach adenocarcinomas were weakly positive for SIP1 expression,
a pattern far beyond the intense SIP1 staining of glandular cells of
normal stomach (Fig. 3C, D). Apical crypt epithelia of 4 normal colon
samples displayed cytoplasmic staining with both antibodies with
moderate intensity, and a faint nuclear SIP1 expression was also
observed in these cells. However, only 4 of 12 colon tumors were
weakly positive for cytoplasmic SIP1 (Fig. 3E, F). In tissue arrays, only
one normal rectum sample was available, and lumen-facing epithelial
cells of this tissue were found to express SIP1 mainly in their nuclei
and to a lesser extent in their cytoplasm. Irrespective of its cellular
localization, SIP1 expression was of moderate to strong intensity in
normal rectum. On the contrary, 78% of rectum tumors were stained,
but with weak immunoreactivity (Fig. 3G, H). The dominant
cytoplasmic staining pattern of these cancer tissues was accompanied
by moderate nuclear staining in only one case, which was the tumor
with most advanced stage among others (data not shown). Tumor
cells of 5 squamous cell carcinoma of the esophagus expressed SIP1,
yet with a weaker intensity than squamous epithelium of normal
esophagus, which was stained with moderate intensity by both
antibodies (Fig. 3I, J).
Cytoplasmic SIP1 is present in tumor cell lines
Cytoplasmic SIP1 expression in the majority of human carcinomas
prompted us to validate this observation in two colon cancer cell lines
(SW620 and SW480) and one hepatocellular carcinoma cell line (SK-rs. Photographs are representative from immunohistochemistry performed by both
s. (A) Normal liver, (B—right) hepatocellular carcinoma (HCC) of the liver and (B—left)
ach, (E) normal colon surface epithelium, (F) adenocarcinoma of the colon, (G) normal
us epithelium, (J) squamous cell carcinoma of the esophagus. +: weak, ++:moderate,
Fig. 4. SIP1 protein is present in nucleus and cytoplasm of carcinoma cell lines.
(A) Western blotting performedwith clone 1C6 shows strong SIP1 expression at 190 kDa in
the nuclear fraction of SK-HEP-1 cells, yet the antibody also detects bands with lower
molecular weight proteins in nuclear (N) and total cell lysates (T) of all 3 cell lines. SIP1
expression is more apparent in the cytoplasmic (C) but not nuclear extracts of SW480 and
SW620cells. SK-HEP-1cells also contain similar levels of cytoplasmic SIP1. (B)Quantiﬁcation
of SIP1 transcripts indicates the highest SIP1 expression in SK-HEP-1 cell line. SIP1 transcript
levels in SK-HEP-1 and SW620 cells are represented as fold changes with respect to SW480
reference cell line.
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SIP1 protein byWestern blotting. A protein band with strong intensity at
the expected size (190 kDa) of SIP1 was observed in the nuclear fraction
of the invasive hepatocellular carcinoma cell line SK-HEP-1 (Fig. 4A).
Weaker protein bands of the same size also appeared in the cytosolic
fractionof SK-HEP-1, and inboth cytosolic andnuclear fractions of SW620
and SW480 cells. However, SIP1 expressionwas barely detectable in total
cell lysates. Besides, SIP1 antibody immunoreactive bands at about
120 kDa and lower molecular weights were also observed in the nuclear
extracts and total cell lysates of all 3 cell lines (Fig. 4A). These resultswere
in accordance with real-time quantitative PCR data in which SK-HEP-1
was the cell line with most abundant SIP1 transcript (Fig. 4B).
Overall, our results indicated that SIP1 was widely expressed in
most normal human tissues that we examined, with moderate to
strong intensities, and the overexpression of SIP1was conﬁned only to
a restricted group of human tumors.
Discussion
SIP1 has been reportedly shown to mediate EMT and disease
aggressiveness in human tumors (Comijn et al., 2001; Elloul et al.,
2005). Several studies indicated increased levels of SIP1 transcripts in
association with invasion and metastasis in cancers with advanced
stages (Imamichi et al., 2007; Miyoshi et al., 2004). However, a
comprehensive study on SIP1 protein expression in human normal
and tumors tissues has not been performed. We produced two MAbs
using the N-terminal 360 amino acids of human SIP1 protein as an
antigen and assessed their immunoreactivity in cell lines and tissue
arrays. As an initial study we downregulated SIP1 and the other
ZFHX1 family member protein, ZEB1, by siRNA in an osteosarcoma
derived cell line and compared the strength and speciﬁcity of the
novel SIP1 antibodies along with 5 different commercial SIP1
antibodies. We found that 1C6 and 6E5 can detect endogenous SIP1,but not ZEB1, in this system strongly and speciﬁcally. We also
observed that, with the exception of Bethyl Labs 474 antibody, all
other commercial SIP1 antibodies are weak or non-speciﬁc. Close
homology between human and mouse SIP1 proteins allowed us to
evaluate the speciﬁcity of novel SIP1 antibodies in overexpression
studies. Immunoﬂuorescence analysis of A431/WTSIP1 cells with Tet-
on doxycycline-inducible wild-type mouse SIP1 expression revealed
nuclear localization of SIP1 in only doxycycline-induced cells. This
result also suggests that 1C6 and 6E5 recognize epitopes shared in
both human and mouse proteins.
Endogenous SIP1 expression was analyzed in HCC cell line SK-
HEP-1 and colorectal cancer cell lines SW480 and SW620. SK-HEP-1 is
a well-known invasive hepatocellular carcinoma cell line (Lin et al.,
1998); SW480 and SW620 cell lines were established from the
primary and metastatic tumors of the same patient, respectively
(Leibovitz et al., 1976). Consistent with the role of SIP1 in inducing
EMT phenotype, we found higher SIP1 transcript levels in SW620 and
SK-HEP-1 cells compared to SW480 cell line. SIP1 expression analysis
in western blot and qRT-PCR was almost consistent with a basal
expression in SW620 and SW480, and an apparent upregulation in
SK-HEP-1. Although there was a ∼15 fold SIP1 overexpression in
metastatic SW620 cells when compared to SW480, the signiﬁcance of
this difference is questionable given the SIP1expression in SK-HEP-1
in thousands scale. Moreover, Western blotting revealed protein
bands other than the expected 190 kDa size of SIP1 protein. In fact, a
comprehensive analysis through human and mouse tissues revealed
multiple transcripts of SIP1 in both species (Bassez et al., 2004). Taken
together with the immunoﬂuorescence data, these results suggest
that SIP1 protein expression is tightly regulated, andmay also indicate
the existence of alternative SIP1 transcripts. However, at this point,
we cannot exclude the possibility of non-speciﬁc signal or protein
degradation for the aforementioned protein bands with lower
molecular weights.
In contrast to nucleus-restricted expression of SIP1 in A431 Sip1
inducible system, most of the analyzed tissues displayed cytoplasmic
protein expression. One explanation might be that while cell lines are
grown in isolation in culture, tissues are subject to signals from their
neighboring cells that may regulate intracellular SIP1 localization.
Additionally, cellular stress induced by continuous culture of cell lines
may affect the intracellular SIP1 destination. Consistent with our
immunohistochemistry ﬁndings, a recent report also indicated
cytoplasmic expression of SIP1 in ovarian tumors (Yoshida et al.,
2009). Strong SIP1 expression in normal epithelial cells including
hepatocytes, kidney tubules, stomach glandular epithelium and colon
surface epithelium suggests the co-existence of E-cadherin and SIP1.
Moreover, SIP1 appears to be prevented from translocating into
nucleus in these tissues. It is therefore plausible to state that, unlike
ZEB1, SIP1 and E-cadherin expression is not necessarily mutually
exclusive. Among the analyzed tissues, most of the normal tissues
expressed SIP1 from moderate to strong intensity, and we found SIP1
overexpression only in kidney, breast, lung and uterus tumors. On one
hand, this differential expression may suggest a protective role for
SIP1 against tumorigenesis. In fact, SIP1 was shown to directly repress
cyclin D1 (Mejlvang et al., 2007). Also, induced expression of SIP1 was
reported to be partly responsible for hTERT repression in hepatocel-
lular carcinoma cells (Ozturk et al., 2006). On the other hand, SIP1
may be implicated in tumor development irrespective of its role in
inducing EMT. In accordance with our results that SIP1 was
upregulated in some tumors, we recently showed that SIP1 protects
cancer cells from DNA damage-induced apoptosis (Sayan et al., 2009).
Also, SIP1 takes part in the TGF-β pathway and the effects of TGF-β on
cells are variable and depend on many factors including cell type and
physiological state of tissues (Massague, 2008; Postigo, 2003).
Given the functional role of SIP1 as a transcriptional repressor, this
and aforementioned studies suggest additional levels of regulation on
SIP1 activity in tumors in a tissue and/or context-dependent manner.
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target genes in conjunction with SMADs and CtBPs. ZEB1 and SIP1 were
shown to have opposing effects on transcriptional regulation (Postigo,
2003). A feedback mechanism was described in which ZEB1 and SIP1
show antagonism by differential recruitment of coactivators and
corepressors to SMAD complexes, respectively (Postigo et al., 2003). In
addition, the expression of ZEB1 and SIP1 was shown to be down-
regulated bymicro RNAs (Gregory et al., 2008). The effects of these post-
transcriptional regulation mechanisms on SIP1 protein might be
explored by using these novel MAbs in further functional studies.
Herein, we performed a pilot study for the understanding of tissue/
tumor speciﬁc SIP1 protein expression with the newly developed SIP1
speciﬁc antibodies using multi-tissue arrays. We showed that SIP1
protein levels increased only in a restricted group of tumors and most
normal tissues displayed SIP1 expression at some extent. We feel to
stress a drawback of staining multi-tumor arrays as the DAB color
reaction has to be stoppedwhen a detectable signal frommajority of the
samples is observed. Thus, our staining is optimal for high/mediumSIP1
expressing tissues andmaybe sub-optimal for lowSIP1 expressingones.
Lower SIP1 expressing tissues may have to be re-tested at their optimal
conditions for the better understanding of SIP1 function in tumor
development. Our recent paper that we analyzed SIP1 expression by
immunohistochemistry and described SIP1 protein overexpression as a
marker of poor prognosis in bladder cancers is a good example that SIP1
can be identiﬁed as a pro-metastatic protein (Sayan et al., 2009).
In conclusion our observation that SIP1 localized predominantly to
the cytoplasm in both tumor and normal tissues suggests the
implication of unidentiﬁed regulatory mechanisms that prevent
translocation of SIP1 into the nucleus. This, in turn, adds another level
of complexity to the control of EMT program in tumors progressing
towards metastatic state. Therefore, our ﬁndings bring novel opportu-
nities to further elaborate the role of SIP1 in tumor development.
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Immunization with UV-Induced Apoptotic Cells Generates
Monoclonal Antibodies Against Proteins Differentially
Expressed in Hepatocellular Carcinoma Cell Lines
HILAL CELIKKAYA,1,3 CEREN CIRACI,1,4 EMIN OZTAS,1,2 M. ENDER AVCI,1
MEHMET OZTURK,1 and TAMER YAGCI1
ABSTRACT
Early and differential diagnosis of hepatocellular carcinoma (HCC) requires sensitive and specific tissue and
serum markers. On the other hand, proteins involved in tumorigenesis are extensively modulated on expo-
sure to apoptotic stimuli, including ultraviolet (UVC) irradiation. Hence, we generated monoclonal antibod-
ies by using UVC-irradiated apoptotic cells of an HCC cell line, HUH7, aiming to explore proteins differen-
tially expressed in tumors and apoptosis. We obtained 18 hybridoma clones recognizing protein targets in
apoptotic HUH7 cells, and clone 6D5 was chosen for characterization studies because of its strong reactivity
in cell-ELISA assay. Subtype of the antibody was IgG3 (). Targets of 6D5 antibody were found to be abun-
dantly expressed in all HCC cell lines except FLC4, which resembles normal hepatocytes. We also observed
the secretion of 6D5 ligands by some of the HCC cell lines. Moreover, cellular proteins recognized by the an-
tibody displayed a late upregulation in UVC-induced apoptotic cells. We concluded that 6D5 target proteins
are modulated in liver tumorigenesis and apoptotic processes. We therefore propose the validation of our an-
tibody in tissue and serum samples of HCC patients to assess its potential use for the early diagnosis of HCC
and to understand the role of 6D5 ligands in liver carcinogenesis.
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INTRODUCTION
HEPATOCELLULAR CARCINOMA (HCC) is one of the most fre-quently occurring cancers worldwide, and in some regions
of Asia, represents the primary cause of death due to cancer.(1,2)
Its incidence continues to increase throughout the world due to
hepatitis B virus (HBV) infections in developing countries,(3)
and hepatitis C virus (HCV) infections(4) and excessive alco-
hol intake(5) in developed western countries and Japan. These
liver-damaging agents lead to liver cirrhosis, which, once es-
tablished, constitutes the major background for HCC develop-
ment.(6) Therefore, patients with liver cirrhosis are periodically
surveyed for the diagnosis of HCC at early stages of tumor de-
velopment. Serum -fetoprotein levels (AFP) and hepatic ul-
trasonography (HUS) are the screening tools of choice,(7) yet
other promising biomarkers, such as des-gamma carboxypro-
thrombin, lens culinaris-agglutinin reactive AFP, human hepa-
tocyte growth factor-1 (HGF-1), insulin-like growth factor-1
(IGF-1), and glypican-3, are currently under intensive investi-
gation.(8,9) However, the sensitivity and the specificity of these
tumor markers for HCC are variable and most of them are not
introduced yet into routine clinical practice.(9) Therefore, the
development of novel markers for HCC with stronger sensitiv-
ity and specificity is of great importance for the surveillance of
patients with liver cancer risk.
Cancer cells develop various strategies, including resistance
to apoptotic stimuli, in order to escape from host immune sur-
veillance mechanisms.(10) They increase the expression of an-
tiapoptotic proteins, while decreasing proapoptotic ones, either
by mutations or epigenetic regulations.(11,12) In order to explore
proteins that are modulated in apoptosis and tumorigenesis pro-
cesses, we produced monoclonal antibodies by using as im-
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munogen UVC-induced apoptotic cells of an HCC cell line,
HUH7. The expression of the targets of clone 6D5 was studied
in both HCC cell lines and apoptosis-induced HUH7 and Ju-
rkat cells. 
MATERIALS AND METHODS
HCC cell lines and antibodies
HCC-derived HUH7, Hep40, Hep3B, Hep3B-TR,
PLC/PRF5, FLC4, SK-Hep1, Focus, Mahlavu, SNU182,
SNU387, SNU398, SNU449, and SNU475 and hepatoblas-
toma-derived HepG2 cell lines were analyzed. SNU182,
SNU387, SNU398, SNU449, and SNU475 cell lines were
grown in RPMI-1640 medium supplemented with 10% fetal
bovine serum (FBS) 100 IU penicillin, 100 g streptomycin,
and nonessential amino acids (RPMI-10). All other cell lines
were grown in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with 10% of FBS, 100 IU penicillin, 100 g
streptomycin, and nonessential amino acids (DMEM-10). Sp2/0
mouse myeloma cells were grown in high-glucose DMEM-10
and used as fusion partner for hybridoma production. A T-cell
leukemia cell line, Jurkat, was grown in RPMI-10. Anticalnexin
monoclonal antibody was a kind gift of Dr. Mehmet Ozturk
(Bilkent University, Ankara, Turkey). Anti-Fas antibody (clone
CH11) was purchased from Upstate Biotechnology (Lake
Placid, NY).
Apoptosis induction in HUH7 and Jurkat cells
Two well-established apoptosis-induction methods, UVC ir-
radiation and anti-Fas treatment, were used for HUH7 and Ju-
rkat cells, respectively.(13) Briefly, HUH7 cells were grown to
80–90% confluency in 10 cm tissue culture plates. Cells were
washed three times with phosphate-buffered saline (PBS) and
exposed to UVC irradiation (20J/M2) in UV-crosslinker appa-
ratus (Stratagene, La Jolla, CA). After the addition of fresh
medium, plates were transferred into CO2 incubator. Jurkat cells
were plated at a density of 5  105/mL and treated for 24 h
with 50 ng/mL of anti-Fas antibody. Both treated and untreated
HUH7 and Jurkat cells were then collected at desired time
points for subsequent apoptosis detection and Western blot as-
says. Apoptosis was analyzed both by examining morphologic
changes under the light microscope and by Annexin V staining
(Annexin V-FITC Apoptosis Detection Kit, Sigma-Aldrich, St.
Louis, MO) of apoptotic cells, according to the manufacturer’s
instructions.
Immunization and production of 
monoclonal antibodies
5–10  106 UVC-treated apoptotic HUH7 cells were scraped
from culture plates and, after washing with PBS, were injected
into the peritoneal cavity of 6- to 8-week-old BALB/c mice
(day 0). Three more injections were repeated at 3 week inter-
vals, and immunization efficiency was assessed on days 25 and
45 by cell-ELISA, as described below. Three days after the last
injection, immunized mice were sacrificed and their spleen cells
were fused with Sp2/0 mouse myeloma cells by standard pro-
tocol.(14) Hybrid cells were plated into 96-well tissue culture
plates in hybridoma growth medium consisting of high-glucose
DMEM supplemented with 20% FCS, 100 IU penicillin, 100
g streptomycin, nonessential amino acids, and hybridoma se-
lection reagents (hypoxantine, aminopterin, thymidine (HAT);
Sigma-Aldrich). Screening of hybrid cells was performed by
cell-ELISA and clones with high absorbance values were sub-
jected to subclonings by limited dilution. Isotype of antibodies
was determined by ImmunoPure Monoclonal Antibody Isotyp-
ing Kit (Pierce, Rockford, IL), according to the manufacturer’s
instructions.
Cell-ELISA
HUH7 cells were plated in 96–well tissue culture plates at a
density of 5  104 cells/well, and UVC irradiation was applied
when cells reached confluency. After 16 h, medium was aspi-
rated from the wells of culture plates and cells were fixed by
100% ice-cold methanol. Next, fixed cells were incubated at
room temperature with supernatant of growing hybridomas for
2 h followed by incubation for 1 h with alkaline phosphatase
(AP) conjugated anti-mouse IgG (Sigma-Aldrich) at 1:1000 di-
lution. Colorimetric reaction was allowed to occur by using
paranitrophenylphosphate (pNPP) substrate solution (pNPP
tablets, Sigma-Aldrich). Plates were read at A405 using a mi-
croplate reader (Beckman, Fullerton, CA). Between each step
of cell-ELISA, wells were washed gently with PBS to prevent
the detachment of fixed cells.
Western blotting
Total cell lysates from 14 HCC and Jurkat cell lines were
prepared in NP-40 lysis buffer (50 mM Tris-HCl pH 8.0, 150
mM NaCl, 1% Non-idet P40 [v/v] and a cocktail of EDTA-free
protease inhibitors [Roche Diagnostics, Mannheim, Germany]).
Protein content was measured by Bradford assay.(15) Equalized
lysates were run on 10% SDS-PAGE and then transferred onto
polyvinylidene fluoride (PVDF) membranes by using semi-dry
transfer apparatus (Bio-Rad Laboratories, Hercules, CA). Mem-
branes were blocked overnight with 5% dry milk in Tris-
buffered saline (TBS) containing 0.1% Tween-20 (TBS-T).
Undiluted 6D5 hybridoma supernatant was used as primary an-
tibody. After washing three times with TBS-T, horseradish per-
oxidase (HRP) conjugated anti-mouse IgG (Sigma-Aldrich)
was used as secondary antibody at 1:5000 dilution. Protein
bands were visualized using ECL Plus chemiluminescent sub-
strate (Amersham, Piscataway, NJ). For equal loading control,
membranes were reprobed with anticalnexin antibody.
Immunofluorescence
HUH7, HepG2, and PLC/PRF5 cells were grown on cover
slips in 6-well plates. PBS was used in all washing steps. Cells
were fixed in 2% paraformaldehyde in PBS and permeabilized
in PBS containing 0.2 % triton X-100. After blocking with 2%
bovine serum albumin (BSA) in PBS, cells were incubated for
2 h at room temperature with undiluted 6D5 hybridoma super-
natant. Fluorescein isothiocyanate (FITC) conjugated anti-
mouse IgG (Sigma-Aldrich) was used as secondary antibody at
1:200 dilution. Nuclei counterstaining was performed with 4,6-
diamidino-2-phenylindole (DAPI); cover slips were mounted on
glass slides and examined under fluorescent microscope (Carl
Zeiss, Göttingen, Germany). Merged images were produced by
using AxioVision image processing software (Carl Zeiss).
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Immunoprecipitation and Western blotting (IP-WB) of
secreted proteins
First serum-free culture media of HCC cell lines were incu-
bated for 2 h at 4°C with 100 L of 6D5 hybridoma super-
natant; then 50 L of protein G agarose beads (East Coast Bi-
ologicals), pre-cleaned with three PBS washes, were added. The
mixture was incubated overnight at 4°C with continuous rota-
tion. Next, beads were precipitated by centrifugation, washed
three times with PBS, and antigen-antibody complexes were
eluted by resuspending beads with an equal volume of 2X SDS-
PAGE sample loading buffer (100 mM Tris-Cl pH 6.8, 4% SDS,
0.2% bromophenol blue, 20% glycerol and freshly added 200
mM DTT). SDS-PAGE and Western blotting were performed
as described above.
RESULTS
Immunization with apoptotic HUH7 cells
To determine the appropriate time for harvesting cells fol-
lowing apoptosis induction, we looked for the presence of apop-
totic cells at various times after ultraviolet irradiation. HUH7
cells were grown on cover slips and exposed to UVC at 20
J/M2. FITC-labeled Annexin V analyses of UVC-treated and
untreated HUH7 cells were performed at 4 h and 24 h post-
UVC treatment. Treated cells displayed strong reactivity with
FITC-labeled Annexin V at both time points, while very low
staining, if any, was observed in unstimulated HUH7 cells (Fig.
1). Therefore, we started immunization of BALB/c mice with
cells harvested at 16 h post-UVC treatment, and we repeated
injections of apoptotic cells at 3 week intervals. The develop-
ment of an immune response in mice sera was assessed by cell-
ELISA, as described in the above Materials and Methods sec-
tion (data not shown).
Production of monoclonal antibodies
Following the fusion of spleen cells of immunized mice with
Sp2/0 myeloma cells, cell-ELISA assays were performed. This
time HUH7 cells were grown to confluency in 96-well tissue
culture plates and then exposed to UVC to screen apoptotic cells
for their immunoreactivity with antibodies secreted by hy-
bridoma clones. We obtained 18 hybridoma clones recognizing
protein targets in apoptotic cells. Out of these, clones 6D5,
6E10, 9C11, and 11G8 displayed higher cell-ELISA absorbance
values, with 6D5 showing highest ELISA titer (data not shown).
All reactive clones were subcloned two times by limiting dilu-
tion, and monoclonal antibody–secreting hybridomas were ex-
panded in culture for supernatant collection and cryopreserva-
tion. Characterization studies were then initiated with 6D5
antibody by reasoning that high cell-ELISA titer of this clone
might correlate with overexpression of its ligands in both HCC
cell lines and cells undergoing apoptosis upon ultraviolet irra-
diation. The isotype of the antibody was found to be IgG3 ().
6D5 recognizes differentially expressed proteins in
HCC cell lines
We first analyzed the immunoreactivity of 6D5 antibody with
whole cell lysates of HCC cell lines. In three separate Western
blot assays, two major proteins with closer molecular weights
of 80 kDa were found to be expressed either alone or con-
comitantly in all studied cells (Fig. 2, upper row). Strong band
intensity suggested an abundant expression of the proteins in
these cell lines. Equal protein loading analysis was performed
by reprobing the membrane with anticalnexin antibody (Fig. 2,
lower row). Lysates of all cells have been shown to contain
equal amounts of total protein, except SK-Hep1 cells, which
displayed a significant decrease in calnexin protein level. This
result repeatedly persisted in independent immunoblots, sug-
gesting a downregulation of this ER chaperone in that cell line.
Cell lines deriving from undifferentiated and invasive tumors,
including SNU475, SNU398, SNU449, SNU387, SK-Hep1,
and Mahlavu, seemed to express 6D5 ligands stronger than did
differentiated HUH7 and HepG2 cell lines (Fig. 2, left and mid-
dle panels). However, no other correlation could be established
between the protein expression patterns and phenotypic char-
acteristics of cell lines. Protein expression was also examined
in two isogenic cell lines, Hep3B and Hep3B-TR, and a third
protein band with lowest molecular weight was observed only
in Hep3B cells (Fig. 2, right panel). These cell lines have been
described elsewhere, and Hep3B-TR cells differ from Hep3B
cells by their resistance to the growth inhibitory effect of TGF-
beta in cell culture.(16) We also compared target protein ex-
pression in HUH7 and FLC4 cells and found that the latter was
totally devoid of any 6D5 ligands (Fig. 3). The hepatoma cell
line FLC4 was established from a well-differentiated HCC and
found to possess normal liver functions.(17,18) We therefore sug-
gest that 6D5 targets are upregulated in HCCs.
6D5 stained the cytoplasm of HCC cell lines
Next we visualized the cellular localization of 6D5 targets
by immunofluorescence microscopy in three HCC cell lines.
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FIG. 1. Annexin V-FITC staining of HUH7 cells after UVC
irradiation. Cells were grown on cover slips in 10 cm culture
plates and then exposed to 20J/cm2 of UVC. Annexin V-FITC
staining was performed at 4 h (A) and 24 h (C) post-UVC treat-
ment. (B and D) Untreated controls of A and C, respectively.
6D5 stained the cytoplasm of HUH7, HepG2, and PLC/PRF5
cells. The strong intensity of the fluorescent signal supported
our observation that proteins recognized by this antibody are
abundantly expressed in HCC cell lines (Fig. 4).
Secretion of 6D5 targets form HCC cells
Protein secretion was searched first in the supernatant of iso-
genic cell lines Hep3B and Hep3B-TR. Cells were cultured up
to 70–80% confluency and then starved for 48 h before the col-
lection of supernatants. This strategy allowed us to eliminate
abundant proteins deriving from fetal calf serum. In the IP-WB
experiment, we detected expression of target proteins only in
the Hep3B culture medium (Fig. 5). A lower band with sharp
intensity and a heavier weak one were observed. However, the
third protein band detected in whole cell lysate of Hep3B cells
(Fig. 2) was absent in IP-WB (Fig. 5). The differential behav-
ior of Hep3B and Hep3B-TR cell lines in protein secretion also
supports our finding that target proteins are differentially ex-
pressed in these cells (Fig. 2). We also analyzed the secretion
of target proteins from other HCC cell lines, including Focus,
HUH7, SNU398, and Mahlavu. Following IP-WB with their
supernatants, we detected faint protein bands in the supernatants
of Focus and SNU398 cells, but not in those of Mahlavu and
HUH7 cells (data not shown).
Effects of apoptosis induction on the expression of
6D5 targets
Next, we examined the modulation of 6D5 ligands in Jurkat
and HUH7 cells treated with anti-Fas antibody and UVC, re-
spectively. Both cells were collected at 24 h post-treatment, and
the expression of 6D5 target proteins was visualized by West-
ern blotting. An induction on protein level was observed for
UVC-treated HUH7 cells, but unexpectedly neither untreated
nor anti-Fas-treated Jurkat cells displayed 6D5 ligand expres-
sion (Fig. 6, upper row). The same membrane was then reprobed
with 9C11 antibody, and target proteins of this clone were found
to be expressed by both cell lines, in both apoptotic and non-
apoptotic conditions. We therefore turned to investigate in more
detail the modulation of 6D5 proteins in HUH7 cells commit-
ted to apoptosis under UVC treatment. We harvested cells at
various time points after UVC irradiation and compared the pro-
tein expression with that of untreated HUH7 cells. As shown
in Figure 7, protein expression was significantly reduced dur-
ing the initial phases of apoptosis (2, 4, and 8 h after treatment),
followed by a recovery at hour 16, with protein levels exceed-
ing those of untreated cells. This recovery was sustained at hour
24 post-UVC treatment, indicating an intermediate-to-late up-
regulation of 6D5 ligands in cells undergoing apoptosis.
DISCUSSION
The choice of HUH7 cells as immunogen is based on our
previous observations that these cells remain attached to cul-
ture plate surfaces even after they commit suicide.(13) In fact,
this property facilitated the collection of cells for immunization
with minimal cell loss and allowed us to perform accurate cell-
ELISA assays. On the other hand, HUH7 cells consist of het-
erogeneous cell populations, which make them an ideal source
for the identification of novel markers for liver tumors, as well
as the characterization of liver precursor cells involved in he-
patocellular carcinogenesis.(19)
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FIG. 2. Expression of 6D5 target proteins in HCC cell lines. Whole cell lysates of HCC cell lines were analyzed in three sep-
arate Western blots. Total protein extracts on PVDF membranes were first probed with 6D5 (upper row) and then with antical-
nexin (lower row) antibodies. Two major protein bands with molecular weight close to 80 kDa were displayed by all cells alone
(HUH7, HepG2, SNU-182, Hep40, SNU-398, SNU-387) or concomitantly (SNU-475, SK-Hep1, Focus, SNU-449, Mahlavu,
Hep3B-TR). Only Hep3B cells expressed a third protein band with the lowest molecular weight. 
FIG. 3. Lack of target protein expression in FLC4 cell line.
Target protein expression of HUH7 cells and FLC4 cells was
compared by Western blotting. Immunoblot was first probed
with 6D5 antibody. No protein expression was observed in
FLC4 cells (upper row). Equal protein loading was controlled
by reprobing the membrane with anti-calnexin antibody (lower
row).
Our Western blot analyses pointed out several important con-
clusions. First, proteins recognized by 6D5 antibody are abun-
dantly and differentially expressed in HCC cell lines, and this
expression appears to increase in poorly differentiated cells.
Second, target proteins are differentially expressed in both cell
lysates and supernatants of Hep3B and Hep3B-TR isogenic cell
lines. The fact that these cells mainly differ in their response to
TGF- suggests a modulation of 6D5 protein expression by this
cytokine-mediated pathway. Third, only FLC4 cell line failed
to express proteins recognized by our antibody. Well-differen-
tiated FLC4 cells are known to have relatively well-preserved
liver cell functions, such as albumin synthesis and enzyme and
drug metabolism activities.(20,21) The absence of target proteins
in these cells resembling normal hepatocytes encouraged us to
suggest the overexpression of 6D5 ligands in hepatocellular car-
cinogenesis. Moreover, we also found that Jurkat cells lack
these proteins and hypothesized that 6D5 ligand expression oc-
curs in a tissue-restricted manner. Taken together, we propose
that 6D5 target proteins are underexpressed in normal liver, up-
regulated in well-differentiated HCC, and attain culmination in
poorly differentiated tumors.
The appearance of multiple bands in our Western blots might
be due to the expression of isoforms and/or post-translationally
modified forms of the 6D5 target protein rather than sponta-
neous protein degradation, since reprobing the membrane with
anti-calnexin antibody revealed single bands in all studied cell
lines. This also led us to seek known HCC markers displaying
different forms and showing the same pattern as 6D5 ligands
in similar studies. The most widely used HCC tumor marker is
AFP, which may be translated from multiple RNA transcripts
(i.e., 2.2, 1.7, 1.6, and 1.35 kb), resulting in the expression of
protein isoforms with molecular weights similar to those of 6D5
target proteins.(22) However, previous studies have clearly
shown that AFP expression is restricted to well-differentiated
cell lines and is absent in others.(23,24) Therefore, according to
our Western blot experiments showing that 6D5 ligands are ex-
pressed in all HCC cell lines regardless of their differentiation
state (Fig. 2), we excluded the possibility that 6D5 antibody is
directed against AFP epitopes. Another protein, which is sub-
jected to intensive investigation, is glypican-3; results from
many studies support its usefulness as a promising marker for
HCC.(8,25) This protein too, when expressed, gives rise to sev-
eral isoforms, whose molecular weights approximate those of
protein bands that we observed in our Western blot analyses.
However, glypican-3 is a proteoglycan bound to the cell mem-
brane through GPI anchor, whereas no membrane staining was
observed on HCC cells in our immunofluorescence assay with
6D5 antibody (Fig. 4). Another group of proteins that displays
differential expression in response to cellular stresses and is
overexpressed in many cancers consists of members of heat
shock proteins (HSP). Most HSPs reside in the cytoplasm and
ER and counteract apoptotic stimuli by preventing misfolding
of proteins.(26) Two important members, with molecular
weights of 70 and 72 kDa, respectively, include Hsp70 and
GRP78/BiP and have been recently reported to be upregulated
in HCC.(27) Their expression was repeatedly shown in Jurkat
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FIG. 4. Immunofluorescence analysis of HCC cell lines with 6D5 antibody. Cells were grown on cover slips and cellular lo-
cation of target proteins in HUH7, HepG2, and PLC/PRF5 cell lines was evaluated by indirect immunofluorescence using 6D5
antibody. DAPI was used for nuclei counterstaining, and merged images were obtained by using image processing software. All
cell lines exhibited strong cytoplasmic staining.
FIG. 5. Secreted forms of 6D5 target proteins. Protein secre-
tion was evaluated in isogenic cell lines Hep3B and Hep3B-
TR. Proteins were immunoprecipitated from serum-free 
supernatants of these cells. Following SDS-PAGE and elec-
troblotting, the membrane was probed with 6D5 antibody. Tar-
get protein bands were detected only in the supernatant of
Hep3B cells. Lower bands appearing in both supernatants cor-
respond to immunoglobulin heavy chain.
cells,(28,29) which failed to display 6D5 ligands both in apop-
totic and nonapoptotic conditions (Fig. 6). We therefore rea-
soned that these proteins could not be the targets of our mono-
clonal antibody.
Immunofluorescence analysis with 6D5 antibody revealed per-
inuclear and granular staining pattern reminiscent of an endo-
plasmic reticulum location and prompted us to investigate the se-
cretion of proteins recognized by our monoclonal antibody.
However, secreted forms of target proteins were observed only
in a limited number of HCC cell lines. Nevertheless, we cannot
exclude the possibility that the levels of secreted proteins by other
cells might be below the detection limit of our IP-WB. There-
fore, it would be useful to screen HCC patients’ sera with our
antibody to validate the tumor marker potential of target proteins.
Tumor cells harbor mechanisms enabling them to bypass
apoptotic cell death, which might result from cellular stresses,
and attack by immune effector cells and anti-cancer therapeu-
tic agents. Proteins involved in apoptotic processes are subject
to differential modulation upon encounter with genotoxic stim-
uli.(30) In our study, we triggered apoptosis by treating HUH7
cells with UVC irradiation and examined the expression of 6D5
target proteins. It has been reportedly shown that protein syn-
thesis is inhibited in cells exposed to UV stress through phos-
phorylation of the  subunit of eukaryotic translation initiation
factor 2.(31,32) One of the latter studies also reported a sustained
suppression of translation for up to 48 h.(31) This is in sharp
contrast with our observation that 6D5 target proteins display
an intermediate-to-late upregulation, which culminates at 24 h
post-UVC treatment.
The gene expression pattern of cells exposed to genotoxic
stresses varies enormously depending on both the experimen-
tal conditions and genetic backgrounds of cells.(33) This phe-
nomenon supports our results that 6D5 ligands are subject to
modulation in our experimental settings based on UVC irradi-
ation. However, taken together with our data showing abundant
expression, as well as secretion of target proteins by HCC cell
lines, we can conclude that the ligands of our antibody are some
of the molecular players involved in liver tumorigenesis. Tar-
get protein identification and examination of the reactivity of
this antibody with tissues and sera of HCC patients would be
useful for the exploitation of 6D5 in diagnostic and prognostic
studies of HCC.
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FIG. 6. Induction of apoptosis in HUH7 and Jurkat cells. Apoptosis was induced in HUH7 and Jurkat cells by UVC and anti-
Fas antibody treatment, respectively. Cells were collected at 24 h post-treatment and analyzed by Western blotting. An induction
on 6D5 target protein expression was observed in HUH7 cells upon UVC treatment. However, no protein expression occurred
in anti-Fas treated and untreated Jurkat cells (upper row). The membrane was also probed with 9C11 antibody obtained from the
same fusion experiment. This antibody recognized proteins in both cell lines in both control and treated cells (lower row). Pro-
tein ligands of 9C11 appear not to be modulated upon apoptosis induction. 
FIG. 7. Intermediate-to-late induction of 6D5 target proteins in apoptotic HUH7 cells. UVC-treated HUH7 cells were collected
at given time points and compared with untreated control by Western blotting. Immunoblot was first probed with 6D5 antibody
(upper row), and equal protein loading was assessed by reprobing the membrane with anti-calnexin antibody (lower row).
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